Molecular mechanisms of acquired gemcitabine resistance in pancreatic cancer by Qin, Li
 MOLECULAR MECHANISMS OF ACQUIRED GEMCITABINE 
RESISTANCE IN PANCREATIC CANCER 
 
 
 
 
 
Li Qin 
 
 
 
Submitted to the faculty of the University Graduate School 
in partial fulfillment of the requirements 
for the degree 
Doctor of Philosophy 
in the Department of Pharmacology and Toxicology, 
Indiana University 
 
November 2014 
 
  
ii 
 
 
 
Accepted by the Graduate Faculty, of Indiana University, in partial 
fulfillment of the requirements for the degree of Doctor of Philosophy. 
 
 
 
 
 
 
 
 
________________________________ 
                                                                                        Jian-Ting Zhang, Ph.D., Chair 
 
 
 
________________________________ 
                                                                                        Nickolay Brustovetsky, Ph.D.                 
Doctoral Committee 
 
 
________________________________ 
                                                                                        Karen E. Pollok, Ph.D.             
September 23, 2014    
 
 
________________________________ 
                                                                                        Ahmad R. Safa, Ph.D.                
 
 
 
________________________________ 
                                                                                        William J. Sullivan, Ph.D.                 
 
 
 
________________________________ 
                                                                                        Jingwu Xie, Ph.D.   
 
 
 
 
 
iii 
 
ACKNOWLEDGEMENTS 
            My love for science was given to me by my sister, my parents and grandparents 
and it is to them that I owe my deepest debt of gratitude. They gave me encouragement 
of endless efforts for pursuing my goals, and the determination and confidence to reach 
them. Their many years of support have been a tremendous source of encouragement.  
            I would also like to express my deepest appreciation to the many fine individuals 
who make up this department, especially the members of my committee, Nickolay 
Brustovetsky, Karen E. Pollok, Ahmad R. Safa, William J. Sullivan, and Jingwu Xie. 
Together they have guided me through this precious journey, and helped me more than 
they can know. A very special thanks goes to Zi-zheng Dong and Jing Qi who have a way 
of making things go right and are always there patiently instructing me and guiding me 
through my projects, and my research would not be so smooth without their help. 
Finally, my gratitude also goes to the many fine scientists, present and passed, who have 
made the Zhang lab such a great place to be. 
            For my advisor I cannot begin to express the depth of my appreciation. JT Zhang 
has been more than my mentor; he has been my benefactor and patron saint. Whatever 
contribution I have made or will make to science I truly owe to his patient instruction 
and counsel. Last but not the least, thanks to the entire faculty, graduate students, and 
staff in Department of Pharmacology and Toxicology for their help and support 
throughout these years. I truly appreciate everyone encountered in my life in United 
States to make my adventure here colorful and unregretful. 
iv 
 
  
Li Qin 
 
MOLECULAR MECHANISMS OF ACQUIRED GEMCITABINE RESISTANCE IN PANCREATIC 
CANCER 
 
Most pancreatic cancer patients receiving gemcitabine chemotherapy eventually 
develop resistance to gemcitabine. To improve survival and prognosis of pancreatic 
cancer patients, better understanding the mechanisms of gemcitabine resistance and 
discovery of new therapeutic targets are required. In this study, I investigated the 
molecular mechanisms of acquired gemcitabine resistance using a stepwise 
gemcitabine-selected pancreatic cancer cell line in comparison to the parental cell line. I 
found that 14-3-3σ is up-regulated in the drug resistant cell line due to demethylation in 
its first exon, and the up-regulation of 14-3-3σ gene expression, in turn, contributes to 
gemcitabine resistance. Intriguingly, I found that demethylation of the 14-3-3σ gene in 
gemcitabine resistant cells is reversibly regulated by DNMT1 and UHRF1. Furthermore, I 
found that 14-3-3σ over-expression causes gemcitabine resistance by inhibiting 
gemcitabine-induced apoptosis and caspase-8 activation possibly via binding to YAP1. 
The finding of demethylation of the 14-3-3σ gene in gemcitabine resistant cells led to a 
hypothesis that other genes may also be changed epigenetically following gemcitabine 
selection. By RRBS (Reduced Representation Bisulfite Sequencing) analysis, 845 genes 
were found to have altered methylation. One of these genes, PDGFD, was further 
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investigated and found to have reversible demethylation at its promoter region in the 
drug resistant cells and contribute to gemcitabine resistance possibly via autocrine 
activation of the STAT3 signaling pathway. Together, these findings not only provide 
evidence that 14-3-3σ and PDGFD over-expression contribute to acquired gemcitabine 
resistance and that reversible epigenetic changes may play an important role in 
acquired gemcitabine resistance, but also demonstrate that the molecular mechanisms 
of acquired gemcitabine resistance in pancreatic cancer cells are complex and 
multifaceted. 
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Introduction 
A. Pancreatic ductal adenocarcinoma (PDAC) 
             Pancreatic cancer ranks the fourth most common cause of human death by 
cancer in the western world, with a 5-year survival rate less than 5% for all stages of the 
disease and a median survival of 6 months after diagnosis, thereby exhibiting the 
poorest prognosis of all solid tumors [1-3]. Pancreatic cancer has an annual mortality 
rate of approximately 95% with over 250,000 patients dying worldwide [4]. In 2014, an 
estimated 46,420 people will be diagnosed with pancreatic cancer in the United States, 
and approximately 39,590 people will die from the disease (please see 
http://www.cancer.org/cancer/pancreaticcancer/detailedguide/pancreatic-cancer-key-
statistics). What makes it so lethal is its stealth, which means that it exhibits no clear 
early warning signs or symptoms and therefore often goes undetected until it is 
advanced and too late for resection. In the vast majority of cases, symptoms only 
develop after pancreatic cancer has already grown and begun to spread.  
             Pancreatic ductal adenocarcinoma, or PDAC, is by far the most common type of 
pancreatic malignancy. Although surgical resection remains the only curative 
intervention and offers the best patient outcome for this disease, surgical removal of 
the tumor is possible in only approximately 15% of the patients [5]. Therefore, the poor 
survival rate is mainly attributed to the late detection of PDAC and emergence of a 
largely drug-resistant phenotype over time.            
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B. Gemcitabine in pancreatic cancer treatment 
             Routine treatment options to improve prognosis in patients with pancreatic 
cancer are limited. Its array of treatments includes but is not limited to chemotherapy, 
radiotherapy, immunotherapy, hormonal therapy, medications, surgery, and nutritional 
therapy. At present, single-agent gemcitabine, which has been considered the standard 
of care since 1997, is recommended as first-line chemotherapy for patients with 
advanced pancreatic cancer and has been extensively studied in phase II and III trials.   
             Gemcitabine is a deoxycytidine analogue and was approved by FDA in 1997 as 
the first-line chemotherapeutic drug for patients with locally advanced or metastatic 
pancreatic adenocarcinoma [6, 7]. It functions by either directly and competitively 
incorporating into DNA or inhibiting ribonucleotide reductase M1 or M2 (RRM1/RRM2) 
to prevent DNA replication and, thereby, interrupting DNA synthesis and inhibiting 
cancer cell growth [8]. However, although gemcitabine is the standard and most 
commonly used drug for treatment of pancreatic cancer, almost all patients would 
eventually develop resistance to this therapeutic agent. Over the past decade, 
numerous trials have been conducted to improve the outcome in patients by 
combination therapies using gemcitabine as backbone. Currently, combinational 
treatments using gemcitabine and other therapeutics have shown some promise but no 
real significant improvements in overall survival rates. So far, gemcitabine with erlotinib, 
an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is the only FDA-
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approved combination treatment for PDAC. Unfortunately, this regimen only has a 
modest effect to prolong median overall survival of patients for less than 2 weeks [9] . 
Although gemcitabine monotherapy or in combination with other agents has become 
standard chemotherapy for the treatment of PDAC, gemcitabine imparts a progression-
free survival interval ranging from 0.9 to 4.2 months only [10]. Therefore, the effect of 
gemcitabine on survival has been disappointing. Due to the characterization of PDAC by 
a high propensity for local invasion and distant metastasis as well as early relapses and 
largely drug-resistant phenotype, overcoming the gemcitabine drug-resistant phenotype 
has become a hot topic in this field. Understanding acquired gemcitabine resistance 
could lead to better improvements in the outcome for patients with pancreatic cancer. 
In order to do so, I strongly suggest that a better understanding of the molecular 
mechanisms by which gemcitabine resistance arises is likely to lead to novel therapeutic 
strategies for the successful treatment of patients diagnosed with pancreatic cancer. 
C. Gemcitabine metabolism and known resistance mechanisms 
             Gemcitabine (2',2'-difluorodeoxycytidine, dFdC)  is a prodrug that requires 
cellular uptake and intracellular phosphorylation into its active metabolites, gemcitabine 
diphosphate and triphosphate [8]. As shown in Figure 1, gemcitabine is transported into 
cells via human equilibrative nucleoside transporter-1 protein (hENT1), where it is 
phosphorylated by the rate-limiting enzyme deoxycytidine kinase (dCK) into 
gemcitabine monophosphate (dFdCMP), and is further phosphorylated into active 
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metabolites, the gemcitabine diphosphate (dFdCDP) and gemcitabine triphosphate 
(dFdCTP) by nucleoside monophosphate kinase (NMPK) and nucleoside diphosphate 
kinase (NDPK) respectively [11, 12]. Gemcitabine triphosphate (dFdCTP) is incorporated 
into DNA, thereby competing with dCTP for incorporation. Once dFdCTP is incorporated, 
two phosphate molecules are split off and thus leave dFdCMP in the DNA chain, while it 
allows only one more deoxynucleoside triphosphate to be incorporated, after which 
DNA replication terminates. dFdCMP is resistant to be removed from the DNA strand by 
proofreading enzymes (i.e., polymerase ε), leading to impairment of their ability to 
repair the DNA strand, which is the mechanism also known as “masked-chain 
termination.” Gemcitabine diphosphate (dFdCDP), on the other hand, inhibits 
ribonucleotide reductase M1 or M2 (RRM1/RRM2) that convert CDP to dCDP, leading to 
depletion of  dCTP pools and facilitating incorporation of dFdCTP into DNA [13]. As 
depicted in Figure 1, gemcitabine has various self-potentiating mechanisms that 
contribute to the maintenance of dFdCDP and dFdCTP levels for prolonged periods of 
time. For example, since dCTP inhibits dCK, decreased dCTP pools from RRM1/RRM2 
inhibition by dFdCDP can result in higher dCK activity and thus an increase in 
phosphorylation of dFdC to its active metabolites. In addition, dFdCTP can inhibit 
deoxycytidylate deaminase (dCMPD), an enzyme that deaminates dFdCMP to its inactive 
form dFdUMP, leading to a potentiation of its own formation.       
             It is known that high intracellular accumulation of dFdCTP and incorporation into 
DNA are associated with greater sensitivity to gemcitabine in preclinical tumor models 
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[14]. Moreover, clonogenic survival assays demonstrated that increased gemcitabine 
concentrations result in a decrease of cell viability, which suggested a prolonged periods 
of time for intracellular retention of active gemcitabine metabolites [15, 16]. The 
intracellular accumulation of active metabolites and cytotoxicity of gemcitabine are 
influenced by multiple factors, such as (a) the dosing schedule, (b) 
phosphorylation/activation by dCK, (c) cellular uptake via hENT1, (d) 
degradation/inactivation through CDA, and (e) genetic factors (e.g., single nucleotide 
polymorphisms in dCK and CDA) [17-20]. 
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Figure 1. Gemcitabine metabolic schema and proposed pharmacological mechanisms 
of gemcitabine and its metabolites. Transportation of dFdC into the cell is mediated by 
hENT1, which is followed by intracellular phosphorylation by dCK to its monophosphate 
dFdCMP, and subsequently into its active dFdCDP and dFdCTP metabolites. dFdCTP is 
incorporated into DNA, thereby competing with dCTP for incorporation. dFdCDP inhibits 
RRM1/2, which prevents the conversion of CDP to dCDP and thus reduced synthesis of 
dCTP, leading to an elevation of intracellular dFdCTP/dCTP ratio and enhanced 
incorporation of dFdCTP into DNA.  
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             Remarkable progress has been made during the last decade toward identifying 
and understanding the complicated signaling pathways that contribute to the initiation, 
progression of PDAC, and signaling pathways that contribute to intrinsic and acquired 
gemcitabine resistance in pancreatic cancers. To date, several molecular markers to 
predict gemcitabine sensitivity have been reported and investigated with or without 
relation to gemcitabine metabolism, including messenger RNA (mRNA) and microRNA, 
as well as genes related to gemcitabine metabolism and transport, such as 
deoxycytidine kinase, ribonucleotide reductase, and human equilibrative nucleoside 
transporter-1 [21-24]. However, the potential use of such markers in clinical settings 
remains limited due to the difficulties in evaluating their protein or mRNA levels in 
clinical samples. For example, accurate quantitative analyses of mRNA from clinical 
samples are often difficult as a result of degradation. Therefore, more reliable methods-
based biomarkers are needed to predict responses to gemcitabine. 
             The most studied gemcitabine resistance mechanisms are the dysregulation of 
the enzymes participating in gemcitabine metabolism pathways, including down-
regulation of transporter hENT1, down-regulation of rate-limiting enzyme dCK, and up-
regulation of RRM1/RRM2 [25-31]. It suggests that the ratio of the expression level of 
these four genes (hENT1 Χ dCK)/ (RRM1 Χ RRM2) decreased progressively with 
development of acquired gemcitabine resistance and, thus, this ratio correlates with 
acquired gemcitabine resistance in pancreatic cancer cells, which may be a useful 
predictive marker for the efficacy of gemcitabine chemotherapy in pancreatic cancer 
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patients [30]. Other studies show changes in a variety of cellular signaling pathways 
such as Akt/mTOR signaling pathway and NF-kB signaling pathway, as well as 
malfunction of proteins involved in cell survival/apoptosis pathway [32-34]. Emerging 
evidence suggests molecular and phenotypic association between gemcitabine 
resistance and acquisition of epithelial-mesenchymal transition (EMT)-like phenotype of 
pancreatic cancer cells [35-39]. This process is also believed to be reminiscent of “cancer 
stem-like cells” characteristics in many cancer systems including pancreatic cancer [40-
43]. EMT has been classified as a unique process by which epithelial cells undergo 
remarkable morphological changes characterized by transition from epithelial 
phenotype (cobblestone phenotype) to mesenchymal phenotype (elongated fibroblastic 
phenotype) with increased motility and invasion [44, 45]. Despite our improved 
understanding, it is crucial to continue efforts toward discovering biomarkers and 
unraveling the molecular mechanisms that support and drive this gemcitabine-resistant 
phenotype, which will ultimately provide means to improve treatment of this deadly 
disease. 
D. 14-3-3 sigma and 14-3-3 family 
             Our lab has previously found that high expression of 14-3-3σ (sigma) associates 
with intrinsic gemcitabine resistance in human pancreatic cancer [46], but whether or 
not 14-3-3σ associates with acquired gemcitabine resistance is not known and needs to 
be investigated. It was previously found that 14-3-3σ protein level was increased 
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significantly in about 71% of human pancreatic cancer tissues compared with matched 
normal tissues, and that the 14-3-3σ protein level in pancreatic cancers correlated with 
lymph node metastasis and poor prognosis of the patients [46]. Importantly, the Kaplan-
Meier survival curves demonstrated a trend of higher patients’ survival with low 14-3-3σ 
expression compared to high 14-3-3σ expression (p=0.06). These evidences suggest that 
14-3-3σ may be used as a potential biomarker and promising therapeutic target for 
treating pancreatic cancer.  
             14-3-3σ, also known as human mammary epithelial marker 1 or stratifin, is a 
member of highly conserved family called 14-3-3 proteins that are present in all 
eukaryotic organisms [47]. 14-3-3 proteins belong to a highly conserved multigene 
family of phosphoserine/phosphothreonine-binding molecules with consensus RSXpSXP-
binding motif and play an essential role in multiple biological processes such as cell 
signaling, cell division, survival and cell death [48-51].  
             Among the seven human 14-3-3 family members (β, ε, θ/τ, ζ, σ, γ, η), 14-3-3σ is 
uniquely induced by p53 activation and has a positive feedback effect on p53 activity in 
response to DNA damage [52]. Therefore, 14-3-3σ might function as a potential tumor 
suppressor. Moreover, 14-3-3σ is a negative regulator of the cell cycle by initiating cell 
cycle checkpoint control after DNA damage, and is also required to prevent mitotic 
catastrophe after DNA damage [53-56]. 14-3-3σ was demonstrated to be induced by 
DNA damage such as γ-irradiation and Adriamycin treatment in a p53-dependent 
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manner [53]. Moreover, exogenously over-expressing 14-3-3σ caused a cellular 
phenotype remarkably similar to that observed following γ-irradiation, with an increase 
in cell size and failure to progress through G2/M cell cycle. These results strongly 
suggest that one of the molecular mechanisms underlying the G2/M cell cycle arrest 
following γ-irradiation is based on the activation of p53, which in turn transcriptionally 
activates 14-3-3σ [53].  Furthermore, 14-3-3σ appears to sequester CDC2-CyclinB1 
complexes in the cytoplasm, causing G2/M cell cycle arrest, and 14-3-3σ knockout fails 
to arrest CDC2-Cyclin B1 complexes in cytoplasm, resulting in mitotic catastrophe 
[55].   In addition, inactivation of CDC25C, an activator of CDC2-Cyclin B1 complex, via 
phosphorylation at serine 216 by serine/threonine protein kinase CHK1, created a 
binding site for 14-3-3 proteins and resulted in cytoplasmic arrest of CDC25C [57, 58]. 
Therefore, 14-3-3 proteins act on both CDC25C and CDC2-Cyclin B1 complexes to ensure 
that mitosis does not occur in the presence of DNA damage [55, 59].  
E. Association of 14-3-3σ expression with drug resistance 
             14-3-3σ was not only found to correlate with intrinsic gemcitabine resistance, it 
was also previously found to contribute to cisplatin resistance, Adriamycin resistance, 
and mitoxantrone resistance in several human cancer cells.  It was found that the 
parental colon cancer HCT116 cells were six times more tolerance  to cisplatin than 
the 14-3-3σ-KO HCT116 cells [60]. In human pancreatic cancer cell lines, it was found 
that in response to cisplatin treatment, 14-3-3σ-over-expressing PANC-1 cells exhibited 
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attenuated PARP cleavage and significantly decreased activation of caspase-3, 
compared with sham-transfected PANC-1 cells. Moreover, T3M4 pancreatic cancer cells 
with silenced 14-3-3σ exhibited an elevated PARP cleavage and caspase-3 activation 
following cisplatin treatment [61]. These findings suggest that 14-3-3σ over-expression 
contributes to intrinsic cisplatin resistance by inhibiting apoptosis. In addition, 14-3-3σ 
over-expression was also found to be associated with acquired cisplatin resistance in 
non-small cell lung cancer cells. It was found that 14-3-3σ mRNA expression levels were 
significantly increased in acquired cisplatin-resistant A549 and Calu1 cells compared 
with parental A549 and Calu1 cells that are cisplatin-sensitive, and that suppressing 14-
3-3σ expression in cisplatin-resistant Calu-1 cells magnified cisplatin response [62].  
             Previous proteomic analysis identified 14-3-3σ as a contributor to acquired 
Adriamycin resistance in breast cancer cells [63]. By utilizing two-dimensional gel 
electrophoresis and mass spectrometry analysis, 14-3-3σ was one of the 17 proteins 
identified with differential expression levels between parental MCF7 cells and acquired 
Adriamycin-resistant cells MCF7/AdVp3000. Further studies by knocking down 14-3-3σ 
expression in these cells as well as ectopic over-expression of 14-3-3σ in parental MCF7 
cells showed that the increased 14-3-3σ expression in resistant MCF7/AdVp3000 cells 
contributed to the drug-resistant phenotype [63].  
             Experiments were also conducted by ectopically over-expressing 14-3-3σ in 
HEK293 cells, and results showed that ectopic over-expression of 14-3-3σ in HEK293 
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cells resulted in increased resistance to mitoxantrone [63]. In addition, by perfoming 
two-dimensional gel electrophoresis, 14-3-3σ was also found to be over-expressed in 
the mitoxantrone-selected atypical multidrug-resistant cell line EPP85-181RNOV, 
suggesting its association with mitoxantrone resistance in human pancreatic 
adenocarcinoma [64].  
             In prostate cancers, it was found that the expression level of 14-3-3σ was much 
higher in androgen-independent prostate cancer cell lines DU145, PC3, and CWR22RV 
than that in the androgen-dependent cell line LNCaP, and that the androgen-
independent cells are more resistant to mitoxantrone and Adriamycin than the 
androgen-dependent cells [65]. Moreover, depleting 14-3-3σ expression in androgen-
independent DU145 and CWR22RV cells significantly sensitized these cells to 
mitoxantrone and Adriamycin treatment by abrogating G2/M cell cycle checkpoint and 
promoting apoptosis, whereas restoring 14-3-3σ expression in androgen-dependent 
LNCaP cells enhanced drug resistance [65]. This study indicates that advanced 
and hormone-refractory prostate cancers may have an increased level of 14-3-3σ, which 
in turn contributes to mitoxantrone and Adriamycin resistance in advanced 
and hormone-refractory prostate cancers. Thus, therapeutic intervention targeting 14-3-
3σ may be useful for sensitizing hormone-refractory prostate cancers to 
chemotherapeutic drugs by both G2/M checkpoint abrogation and apoptosis 
enhancement.   
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             Our lab has previously found that high expression of 14-3-3σ associates with 
intrinsic gemcitabine resistance in human pancreatic cancer, and that over-expression of 
14-3-3σ caused resistance to γ-irradiation and anticancer drugs including Adriamycin, 
mitoxantrone, and gemcitabine in pancreatic cancer cell lines [46]. Therefore, 14-3-3σ 
may serve as a prognosis marker predicting survival of pancreatic cancer patients. 
Despite the evidence that high 14-3-3σ expression level contributes to intrinsic 
gemcitabine resistant in pancreatic cancer cell lines and prognosis in pancreatic cancer 
patients, it is unknown if and how 14-3-3σ contributes to acquired gemcitabine 
resistance. 
F. YAP1, a potential binding partner of 14-3-3σ 
             As a chaperon protein, the potential contribution of 14-3-3σ to drug resistance 
may be by regulating its binding partners. One potential binding partner of 14-3-3σ is 
called YAP. YAP is a 65 kDa protein (sometimes termed YAP65 or YAP1) that was 
originally identified due to its interaction with the Src family tyrosine kinase Yes [66]. 
YAP is a transcriptional coactivator without a DNA-binding motif while maintaining a 
potent transactivation domain at its C terminus [67]. Thus it binds and activates several 
transcription factors including Runx [67] and four highly conserved TEAD/TEF 
transcription factors [68]. Structurally, it contains a proline-rich domain, a TEAD-binding 
domain, either one or two WW domains depending on alternative splicing [69], a SH3-
binding motif, a transactivation domain (TAD), and a PDZ interaction motif.  The WW 
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domain is the domain for protein-protein interaction, while the N terminus of YAP has a 
binding domain for the TEA domain (TEAD) family of DNA-binding proteins, which have 
been linked to the growth-promoting function of YAP [68]. These DNA-binding proteins 
include other possible transcriptional partners for YAP (ErbB, Runx2, and chromatin 
modeling proteins) as well as the negative YAP regulator LATS (large tumour suppressor) 
kinase [69-72]. Through its carboxyl terminus, YAP was reported to bind to the PDZ-
containing protein EBP50, a submembranous scaffolding protein [73]. 
             By transducing signals from cytoplasm to nucleus, YAP is important for 
transcriptional regulation. The important role of YAP was first discovered 
in Drosophila, where its homolog, Yorkie, was shown to promote tissue growth by 
increasing cell proliferation and inhibiting apoptosis [72]. Genetically, Yorkie is the 
ultimate effector of the evolutionarily conserved Hippo pathway [72]. The localization of 
YAP is controlled by phosphorylation. Five phosphorylation sites (S61, S109, S127, S164, 
S381) of YAP have been described and various kinases from Hippo-like pathways 
including LATS have been shown to be directly involved in the subcellular localization, 
transcriptional coactivator activity and biological functions of YAP [74-77]. Once 
phosphorylated at a key serine (S127), YAP is sequestered in the cytoplasm, where it can 
no longer function to promote target gene expression [78].  
             YAP was also found to bind to apoptosis-related proteins or transcription factors 
including p53 binding protein-2 (p53BP-2) [79], an important regulator of the apoptotic 
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activity of p53 [80]. YAP also interacts with the p53 family member p73, resulting in an 
enhancement of p73's transcriptional activity [81]. Since YAP is homologous to TAZ (45% 
identity), a transcriptional coactivator that is regulated by interaction with 14-3-3 [82], it 
may also potentially bind to 14-3-3 proteins. It was reported that YAP phosphorylation 
by Akt induces its interaction with 14-3-3 and suppresses its ability to promote p73-
mediated transcription of pro-apoptotic genes in response to DNA damaging agents [83]. 
More importantly, the crystal structure of 14-3-3σ/YAP phosphopeptide with pSer127 
complex has been resolved with 1.15 Å resolution [84]. However, whether or not YAP 
interacts with 14-3-3σ needs to be further investigated. 
G. 14-3-3σ gene methylation in cancers 
             For a long time, cancer has been widely recognized as a complex disease 
characterized by both multiple genetic and epigenetic alterations [85, 86]. Epigenetic 
regulations like chromatin modifications are known to exert a significant impact on gene 
expression. Several chromatin-modifying enzymes have been identified and known to 
catalyze specific modifications including methylation, acetylation, phosphorylation and 
ubiquitination. DNA methylation is one of the most important epigenetic alterations and 
plays a critical functional role in various biological and physiological processes including 
development, differentiation and progression of various diseases such as tumorigenesis 
[87-90]. Hypermethylation of important genes including tumor suppressor genes has 
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been extensively studied and frequently described in many human cancers including 
pancreatic cancer [91-97]. 
             14-3-3σ has been found to be frequently lost or decreased in various human 
tumors (Table 1) including breast cancer [98], esophageal squamous cell carcinoma [99],  
human oral squamous cell carcinoma [100], salivary gland adenoid cystic carcinoma 
[101], gastric carcinoma [102], urinary bladder carcinoma [103], and prostate cancer 
[104]. Its inactivation in these human cancers is broadly believed to be caused by 
promoter hypermethylation, which leads to block of DNA transcription and results in 
gene silencing [98, 101-104]. However, whether or not and how the methylation status 
of 14-3-3σ gene is regulated during development of acquired gemcitabine resistance is 
not known. 
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Table 1. Frequency of 14-3-3σ gene methylation in different types of cancers. 
Type of cancer Frequency 
Sample 
size References 
Basal-cell carcinoma 
Benign prostate hyperplasia 
Breast cancer 
68% 
100% 
86% 
41 LMT 
29 (MT) 
50 (T) 
[105] 
[104] 
[54] 
Breast cancer 100% 32 (MT) [54] 
Breast ductal carcinoma in situ 83% 18 (MT) [106] 
Breast invasive ductal carcinoma 96% 25 (MT) [106] 
Gastric carcinoma 43% 60 (T) [102] 
Hepatocellular carcinoma 
Large-cell lung cancer 
Non-small-cell lung cancer 
Oral squamous-cell carcinoma 
Prostate carcinoma (Pca) 
Prostate intraepithelial neoplasia (high-grade) 
89% 
57% 
6% 
35% 
99% 
100% 
19 (T) 
7 (L) 
17 (L) 
92 (T) 
121 (MT) 
39 (MT) 
[107] 
[108] 
[108] 
[109] 
[104] 
[104] 
Small-cell lung cancer 69% 13 (L) [108] 
Small-cell lung cancer 33% 24 (ML) [108] 
Urinary bladder carcinoma (invasive) 57% 14 (MT) [103] 
Urinary bladder carcinoma (noninvasive) 21% 14 (MT) [103] 
Vulval pre-malignant neoplastic lesions VIN III  
Vulval squamous-cell carcinoma 
59% 
55% 
22 (T) 
36 (T) 
[110] 
[110] 
L, cell line; LMT, laser-microdissected tumour; MT, microdissected tumour; T, non-
dissected tumour; VIN III, vulval intraepithelial neoplasia 
  
[110] 
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H. Uhrf1/DNMT1 complex, an emerging regulator of gene methylation 
             It is well known that DNA methylation is established and maintained by three 
active DNA methyltransferases, DNMT1, DNMT3a, and DNMT3b [111, 112]. 
Both DNMT3a and DNMT3b are regarded as de-novo DNA methyltransferases, 
whereas DNMT1 has a strong preference for hemi-methylated CpG substrates 
generated during DNA replication and is regarded as maintenance DNA 
methyltransferase [111-113]. Consistent with its central role in maintenance of DNA 
methylation, DNMT1 is associated with DNA replication forks in the S phase of cell cycle 
[114, 115], making it a good target for studying epigenetic alteration or inheritance 
during biological and pathological processes. Recent studies have focused on the central 
topic how DNMT1 is recruited to the DNA replication foci. 
             Recently, Uhrf1 (ubiquitin-like, containing PHD and RING finger domains 1) was 
identified as a DNMT1-interacting protein that recruits DNMT1 to replication forks to 
maintain DNA methylation and hence Uhrf1 is essential for epigenetic inheritance [116, 
117]. Uhrf1 is a multi-domain protein associated with cell proliferation and epigenetic 
regulation, and is a putative oncogenic factor that is found over-expressed in numerous 
cancers [118, 119]. Structurally, it harbors an ubiquitin-like domain, a plant 
homeodomain (PHD), a Set and Ring Associated (SRA) domain and a RING domain.  It is 
considered an efficient marker to differentially diagnose pancreatic adenocarcinoma, 
chronic pancreatitis and normal pancreas [120].  Moreover, Uhrf1 was also found to be 
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over-expressed in bladder cancer and the intensity of its over-expression appears to be 
related to the stage of the cancer, suggesting Uhrf1 as a novel molecular marker for 
diagnosis and prognosis of bladder cancer [121]. Furthermore, Uhrf1 could bind to 
histones and methyl-CpG dinucleotides with a preference for hemimethylated CpG sites 
via a unique SRA domain which is found only in Uhrf family [122, 123]. The consequence 
of Uhrf1 binding is recruitment of transcriptional repressors like DNMT1 (Figure 2) and 
histone deacetylase 1 (HDAC1) along with PCNA, resulting in methylation of the newly 
synthesized strands, which plays an important role in facilitating and maintaining DNA 
methylation in human genome [124-128]. Therefore, Uhrf1 is hypothetically involved in 
a macro-molecular protein complex called "Epigenetic Code Replication Machinery" that 
would be able to duplicate the epigenetic code by acting at the DNA replication fork and 
activating the right enzymatic activity at right moment [129, 130].  
             The ultimate outcome of Uhrf1 binding is repression of its target genes. By 
forming a complex with HDAC1, Uhrf1 was found to bind to methylated promoter 
regions of tumor suppressor genes such as p16 and p14 in cancer cells [131]. Moreover, 
Uhrf1 was also found to cooperate with G9a to enhance the transcriptional repression 
of p21 gene [132]. Furthermore, Uhrf1 was found to be over-expressed in colorectal 
cancer tissues to promote colorectal cancer growth and metastasis by repressing 
p16ink4a [133]. In addition, other tumor suppressor genes were also identified to be 
negatively regulated by Uhrf1, including RB1 and BRCA1 [127, 134]. However, whether 
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the putative tumor suppressor genes such as 14-3-3σ are epigenetically regulated by 
Uhrf1 needs to be investigated. 
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Figure 2. A successive DNA transfer model for maintenance DNA methylation by Uhrf1 
and DNMT1. Schematic model showing cooperative action by Uhrf1 and DNMT1 for 
maintenance of DNA methylation. Uhrf1 recognizes and binds to hemi-methylated CpG 
sites of the genome, leading to the recruitment of DNMT1 to the site and transfer of 
hemi-methylated DNA to DNMT1, followed by subsequent methylation of newly 
synthesized strand by DNMT1 to maintain DNA methylation. Pre-existing and newly 
synthesized DNA strands are indicated by red and blue lines, respectively.  
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I. Platelet-derived growth factor (PDGF) family 
             Platelet-derived growth factor (PDGF) signaling pathway has been extensively 
studied and well characterized since PDGF was first described in 1970s as a serum factor 
that promoted the smooth muscle cell proliferation [135]. The PDGF family comprises of 
four different polypeptides encoded by different genes, which have been identified as 
PDGF-A, PDGF-B, PDGF-C and PDGF-D [136-138]. PDGFs need to be assembled into 
disulfide-bonded dimers via homodimerization or heterodimerization in order to play 
their functional role. To date, four homodimers PDGF-AA, PDGF-BB, PDGF-CC and PDGF-
DD, and one heterodimer PDGF-AB have been described [139]. It is noteworthy that no 
heterodimers involving PDGF-C and PDGF-D chains have been identified. In addition, it is 
notable that PDGF-A and PDGF-B are secreted in their active forms, while PDGF-C and 
PDGF-D are secreted as inactive forms, requiring further activation for their function 
[136, 140, 141]. Structurally, as shown in Figure 3A, PDGF-A and PDGF-B mainly encode 
the growth factor domain and have short N-terminal extensions that undergo 
intracellular proteolytic processing for activation. However, both PDGF-C and PDGF-D 
encode a unique N-terminal CUB (for complement C1r/C1s, Uegf, Bmp1) domain, which 
is cleaved extracellularly followed by secretion for activation [142]. The domain 
structures of PDGF family members are provided in Figure 3A. 
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Figure 3. PDGF proteins and PDGF-PDGFR interactions. (A) Schematic drawing of the 
structure of four PDGF proteins (PDGF-A, B, C and D). (B) Representation of the PDGF-
PDGFR interactions. The extracellular region of the PDGF receptor (PDGFR) consists of 
five immunoglobulin-like domains (shown as blue or red balls) while the intracellular 
part is the tyrosine kinase domain (shown as blue or red rectangles).  
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             PDGFs exert their cellular effects by activating two structurally related receptor 
tyrosine kinases (PDGFR), PDGFR-α and PDGFR-β by phosphorylation [136, 137, 143, 
144]. As shown in Figure 3B, the PDGF-AA activates PDGFR-α, whereas PDGF-BB 
activates PDGFR-α, PDGFR-α/β or PDGFR-β. PDGF-AB and PDGF-CC activate either 
PDGFR-α or PDGFR-α/β, while PDGF-DD specifically binds to and activates its cognate 
receptor PDGFR-β (homo or hetero- dimmers). Although all four PDGF ligands play their 
oncogenic roles through binding with two PDGFRs, they promote carcinogenesis 
through different targets. Specifically, the phosphorylation of PDGFR by PDGFD triggers 
a number of downstream signaling pathways including activation of phosphatidylinositol 
3 kinase (PI3K), Akt, nuclear factor-κB (NF-κB), Notch, and extracellular signal-regulated 
kinase (ERK) [139, 145-147].  
J. PDGFD over-expression in human cancers 
             PDGFD has generated considerable interest in recent years because of its up-
regulation and involvement in the progression of several types of human cancers [147-
153]. Although PDGFD was discovered over a decade ago, the functional role of PDGFD 
is just beginning to be understood. A growing body of literature strongly suggests that 
PDGFD may function as a key player in the development and progression of numerous 
human cancers by regulating the processes of cell proliferation, apoptosis, migration, 
invasion, angiogenesis, and metastasis [139, 153-156]. It has been reported that PDGFD 
signaling is frequently deregulated in human malignancies with up-regulated expression 
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of PDGFD in prostate, lung, renal, ovarian, brain, and pancreatic cancers [146, 147, 149-
152]. Over-expression of PDGFD in breast cancer cells was found to promote tumor 
growth and lymph node metastasis through increased proliferation and decreased 
apoptosis via activation of MAPK and Akt signaling pathway [157]. In pancreatic cancer, 
PDGFD was reported to be strongly expressed in pancreatic adenocarcinomas, reactive 
cells of chronic pancreatitis, and in islets, but to a lesser degree in the normal ducts 
[147]. These findings make PDGFD a promising target for improvement in therapeutic 
treatment of pancreatic cancers. However, the association of PDGFD over-expression 
with resistance to therapeutic agents has not been extensively studied. PDGFD was only 
shown to be identified as one of the key genes that influenced semustine 
chemosensitivity in glioblastoma [158]. Also, in postate adenocarcinoma, increased 
PDGFD expression in PTEN knockout cells was shown to contribute to radio resistance 
observed in these cells [154]. However, whether or not and how PDGFD associates with 
gemcitabine resistance is unknown. 
K. Specific aims of the present work 
             As discussed above, one of the major obstacles in successful treatment of 
pancreatic cancer is the development of drug resistance that makes the patients 
unresponsive to drug treatment and eventually leads to poor prognosis. Although 
gemcitabine is the first-line therapy used for treating pancreatic cancers, acquired 
gemcitabine resistance in a substantial number of patients appears to hinder its 
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effectiveness. Extensive studies have been carried out in the cancer research 
community to understand the mechanisms responsible for drug resistance in a hope to 
discover potential therapeutic targets for prognosis and therapeutic treatments of 
pancreatic cancer patients. However, progress in our understanding of acquired 
gemcitabane resistance has been very slow and more studies are needed. 
             To further investigate the mechanisms of gemcitabine resistance, a gemcitabine 
resistant pancreatic cancer cell line was generated by stepwise selection of a pancreatic 
cancer cell line MiaPaca-2 with increasing concentrations of gemcitabine. The resistant 
cell line was cloned and named G3K, and can survive and grow in the presence of 3000 
nM of gemcitabine; this is ~6,500 (relative resistance factor or RRF) fold more resistant 
to gemcitabine than the parental MiaPaca-2 cells. In addition to the up-regulation of 
known gemcitabine resistant enzymes such as ribonucleotide reductase M1/M2 (RRM1 
or RRM2), the expression of 14-3-3σ protein, but not other 14-3-3 family members, was 
dramatically increased in the resistant cells. Furthermore, our data indicate that 14-3-3σ 
up-regulation is widely recognized to be caused by gene demethylation of its first exon. 
             Therefore, the first aim of my present work is to investigate the detailed 
mechanism through which gemcitabine selection causes 14-3-3σ gene demethylation. 
By examining the DNA methyltransferases (DNMT1, DNMT3a, and DNMT3b) and the 
recruiter Uhrf1, I found that DNMT1 and Uhrf1, but not DNMT3a or DNMT3b, play a 
critical role in 14-3-3σ gene methylation, and knocking down expression of either one 
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leads to 14-3-3σ gene re-expression. Moreover, by ChIP assay, I found that Uhrf1 could 
recruit DNMT1, and both proteins bind to the methylated region of 14-3-3σ gene, 
demonstrating an important role of these two proteins for maintaining the methylation 
status of 14-3-3σ gene. Moreover, gemcitabine selection leads to the reduced 
expression of Uhrf1, which results in a decreased recruitment of DNMT1 to the 14-3-3σ 
gene and eventually leads to the 14-3-3σ gene demethylation. Because the altered 
expression of Uhrf1 and DNMT1 in G3K cells likely also influence the methylation status 
of other genes, which may also contribute to acquired gemcitabine resistance, the 
second aim was designed to profile global changes in gene methylation comparing 
MiaPaca-2 and G3K cells using Reduced Representation Bisulfite Sequencing (RRBS). 
Among 845 genes that have been found to have altered methylation, PDGFD was shown 
to play an important role in acquired gemcitabine resistance possibly by regulating 
STAT3. The third aim was designed to investigate the detailed mechanism of 14-3-3σ-
mediated gemcitabine resistance in pancreatic cancer cells. My studies showed that 14-
3-3σ over-expression protected cancer cells from gemcitabine-induced apoptosis likely 
by forming a complex with YAP1 and together inhibiting caspase-8 activation and 
gemcitabine-induced apoptosis.  
             The outcome of this study shall lead to a better understanding of epigenetic 
regulation of 14-3-3σ gene and molecular mechanisms of acquired gemcitabine 
resistance in pancreatic cancer, particularly the mechanism of PDGFD-mediated 
gemcitabine resistance. It may also help discover potential therapeutic targets and 
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develop better antineoplastic drugs and treatment regimens that maybe more effective 
for drug resistant pancreatic cancer patients. Moreover, this study strongly suggests 
that reversible epigenetic regulation may play an important role in development of 
acquired gemcitabine resistance in pancreatic cancer patients and targeting epigenetic 
regulation may provide a new direction for chemosensitization of gemcitabine resistant 
human pancreatic cancers. 
 
 
 
 
 
 
 
 
 
29 
 
MATERIALS AND METHODS 
A. Materials 
             Metafectene Pro transfection reagent was obtained from Biontex. siRNAs 
targeting 14-3-3σ (sc-29590), YAP1 (sc-38637), Uhrf1 (sc-76805), DNMT1 (sc-35204), 
DNMT3a (sc-37757), DNMT3b (sc-37759) as well as PDGFD (sc-39709) and antibodies 
against 14-3-3θ (sc-732), 14-3-3ζ (sc-1019), DNMT1 (sc-135887), and DNMT3a (sc-20703) 
were purchased from Santa Cruz Biotechnology. Antibodies against GFP (ab290), YAP1 
(ab52771), p-YAP1 (ab76252), TRPC3 (ab70603), and DNMT1 (ab13537) antibody for 
ChIP assay were from Abcam. Antibodies against 14-3-3σ (05-632), RRM1 (MABE567), 
ChIP Assay kit (17-295), and CpGenome Universal DNA Modification kit (17-295) were 
purchased from EMD Millipore. Antibodies against Uhrf1 (612264) and FASN (610963) 
were from BD Biosciences. Antibodies against histone H3 (9715), p-STAT3 (9145), STAT3 
(9139), Caspase-8 (9746), and Parp-1 (9542) were from Cell Signaling. Antibodies against 
hENT1 (T0108), PDGFD (SAB1101911), and RRM2 were from Epitomics, Sigma, and 
generated in-house [159], respectively. Lipofectamine, pcDNA3.1(+) plasmid, and G418 
were from Invitrogen. PDGFD cDNA was purchased from Thermo Scientific. RNeasy Mini 
kit and Qiagen Blood and Cell Culture DNA Kit were from Qiagen. The iScriptTM cDNA 
synthesis kit and the SYBR Green PCR master mix were from Bio-Rad and Applied 
Biosystems, respectively. Gemcitabine were purchased from Besse Medical whereas 
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Ara-C, 5-FU, Adriamycin, mitoxantrone, and nocodazole were form Sigma. All other 
chemicals were purchased from Sigma or Fisher Scientific. 
B. Cell lines, cell cultures, and transfections  
             Human pancreatic cancer cell line MiaPaca-2 (ATCC) and its derivative lines G3K 
and G3KRev were cultured at 37℃, 5% CO2 in DMEM medium supplemented with 10% 
fetal bovine serum and 2.5% horse serum. G3K cells were generated by stepwise 
selection of MiaPaca-2 using gradually increasing concentrations of gemcitabine starting 
at 4 nM. G3K cells were clonal and maintained in the presence of 3 µM gemcitabine. The 
G3KRev cell line was generated by culturing the drug-resistant G3K cells in the absence 
of gemcitabine for six months and partially lost its gemcitabine resistance phenotype. 
Human pancreatic cancer cell line Aspc-1 was a gift from Dr. Jingwu Xie (Indiana 
University) and was cultured in RPMI medium supplemented with 10% FBS. MCF7 and 
its derivative lines MCF7/AdVp3000, and MCF-7/AdVpG3K/REV were gifts from Dr. 
Susan E. Bates (National Cancer Institute) and cultured as previously described [63]. The 
cell lines were authenticated by analysis of tandem repeat sequences on September 17, 
2013. 
             For transient knockdown or over-expression of target genes, cells were plated in 
a six-well plate at a density of 1.5-3×105 cells/well and cultured overnight in complete 
medium. About 60-120 pmol siRNAs of target genes or control scrambled siRNAs, or 1-
2μg of over-expressing plasmid of target genes or vector control plasmid were diluted in 
31 
 
serum-free Opti-MEM medium and then transiently transfected into cells using 
Metafectene Pro transfection reagent as previously described [160].  
             For stable transfection, the cDNA of 14-3-3σ and PDGFD gene was engineered 
into pcDNA3.1(+) and transfected into MiaPaca-2 cells using Lipofectamine and 
Metafectene respectively. Stable clones were selected using 1 mg/ml G418 as previously 
described [63, 65]. The stable clones were maintained in complete medium 
supplemented with 200 μg/ml G418. 
             Similarly, the stable shRNA knockdown was generated as previously described 
[63, 65]. Briefly, G3K cells were transfected with pSilencer-σ (14-3-3σ shRNA cloned into 
pSilencer 3.1-H1neo vector) or scrambled shRNA construct [63, 65] using Lipofectamine 
followed by selection with 1 mg/ml G418 for 2 weeks. Individual clones were tested for 
14-3-3σ knockdown and positive clones were propagated and maintained in complete 
DMEM medium. 
C. Cell lysate preparation, TCA protein precipitation and Western blot 
             Cultured cells were harvested, washed with PBS, and lysed in TNN-SDS buffer (50 
mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% Nonidet P-40, 50 mM NaF, 1 mM sodium 
orthovanadate, 1 mM dithiothreitol, 0.1% SDS, and 2 mM phenyl-methylsulfonyl 
fluoride) for 30 minutes at 4°C with constant agitation. The cell lysates were then 
sonicated briefly and followed by centrifugation (14,000×g at 4°C) for 15 minutes to 
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remove insoluble materials. The protein concentrations of supernatants were measured 
by Bradford assay. 
             Cell lysates were separated by SDS-PAGE and transferred to a PVDF membrane 
followed by a 2-hr incubation in blocking solution (PBS-buffered saline containing 5% 
nonfat dried milk and 0.1% Tween 20) and a 2-hr incubation with primary antibodies. 
After extensive washing, immunoreactivity was detected with specific secondary 
antibodies conjugated to horseradish peroxidase. Signals were captured using ECL x-ray 
film. 
             For the detection of secreted proteins, 1 volume of TCA (100% w/v) was added 
to 4 volumes of protein samples collected from the conditioned medium, followed by 
incubation for 40 minutes at 4°C and centrifugation (14,000×g at 4°C) for 5 minutes to 
precipitation all proteins. After aspirating the supernatant, the protein samples were 
washed twice with pre-cold acetone, followed by centrifugation (14,000×g at 4°C) for 5 
minutes. After removing the supernatant and air-dry, protein samples were solubilized 
by adding 2Χ loading buffer and ready for SDS-PAGE. When comparing two or more 
protein samples, the volume of 2Χ loading buffer was calculated based on cell numbers 
at the same time the conditioned medium was collected. 
D. Membrane preparation  
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             The membrane vesicles were prepared as described previously [161]. Briefly, the 
cells were washed with ice-cold PBS and resuspended in hypotonic lysis buffer (10 
mM KCl, 1.5 mM MgCl2, 10 mM Tris-HCl, pH 7.4, 2 mM PMSF) at 1 × 10
6 cells/ml 
followed by being homogenized 100 strokes with glass homogenizer and centrifugation 
at 4,000 × g for 10 min at 4°C. Crude membranes were obtained by centrifugation of the 
4,000 × g supernatant at 100,000 × g for 1.5 hrs. The crude membrane pellet was then 
resuspended in STBS (250 mM sucrose, 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 
mM PMSF), passed through a 26-gauge needle for 20 times, aliquoted, and stored at 
−80 °C.  
E. Survival and apoptosis assay  
             Survival assay was performed as previously described using MTT colorimetric or 
colony formation assay [46, 162]. Briefly, cells were seeded in 96-well plate at 2000-
3000 cells/well and cultured for 24 hrs followed by treatment with different dose of 
anticancer drugs and incubated continuously for 3 days followed by addition of MTT (5 
mg/ml) to a final concentration of 0.5 mg/ml and incubation of the plates at 37°C for 4 
hours. The OD570nm and OD630nm were measured using an automated plate reader and 
analyzed using GraphPad Prism software to generate fitted curve and IC50. Relative 
resistance factor (RRF) is calculated using the following formula: RRF=IC50(test)/IC50(control). 
For apoptosis assay, photometric enzyme immunoassay using a Cell Death Detection 
ELISA Plus kit (Roche Diagnostics, Indianapolis, IN) was performed for quantitative in 
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vitro determination of cytoplasmic histone-associated DNA fragments and apoptosis as 
previously described [163]. 
F. Quantitative real-time RT-PCR  
             Quantitative RT-PCR was performed as described previously [164, 165]. Briefly, 
total RNA was extracted using RNeasy Mini Kit followed by reverse-transcription using 
iScriptTM cDNA synthesis kit and quantitative PCR using the SYBR Green PCR master mix. 
The primer pairs used are: 5′-TAGGCGCTGTTCTTGCTCCAA-3′ (forward) and 5′- 
ACCAGTGGTTAGGTGCGCTCA-3′ (reverse) for 14-3-3σ; 5′-GGCAAGTTCTCCGAGGTCTCTG-
3′ (forward) and 5′-TGGTACATGGCTTTTCGATAGGA-3′ (reverse) for DNMT3b, 5’-
TCTGGCTTTCTTTGCAGCAA-3’ (forward) and 5’-CAGCGGGCTTCTGTAATCTGA-3’ (reverse) 
for RRM2; 5′-GCCTTTACCGTCACCCTTATC-3′ (forward) and 5′-
AAAGGTACTACTTATGGGGGC-3′ (reverse) for PTPRG; 5′-GTGTCCCGCTCAGGTATAAAAG-3′ 
(forward) and 5′-GGGACCACATTCTCAAAGAGAC-3′ (reverse) for Adora2B; 5′-
CCCCTTCCAACCAGAATGTA-3′ (forward) and 5′-TGCCAAGAGAAACTGCTGAA-3′ (reverse) 
for DUSP6; 5′-CCCCAAAAGTAGCGTAACCA-3′ (forward) and 5′-CCGGTACTCCTGCGTGTTA-
3′ (reverse) for Olig1; 5′-TGAACACCCTGGGCTCTATC-3′ (forward) and 5′-
GGCAGCTGGTCTCCACTTAG-3′ (reverse) for SLC35D3; 5′-CACCTCGGACTCTGTGTTCA-3′ 
(forward) and 5′-AAGGGCAACATGAGAGCTTG-3′ (reverse) for Cdc42EP3; 5′-
CGTGGTCAGGTTGTTTGATGTG-3′ (forward) and 5′-ACTCGGTGTGAATGAAGAAAGTCC-3′ 
(reverse) for CDK6; 5′-ATTGCGATTTCGTGGTGTACAT-3′ (forward) and 5′-
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CCATATTCACCAGTGCTGCTCTT-3′ (reverse) for SLC25A27; 5′-CCCAGGAATTACTCGGTCAA-
3′ (forward) and 5′-ACAGCCACAATTTCCTCCAC-3′ (reverse) for PDGFD; 5′-
GGCCGCACGACTATTTCT-3′ (forward) and 5′-AGCCCCTTGTAGGCATTG-3′ (reverse) for 
TRPC3; 5′-AAGGACTCATGACCACAGTCCAT-3′ (forward) and 5′-CCATCACGCCACAGTTTTC-
3′ (reverse) for GAPDH. 
G. Immunofluorescence and confocal microscope imaging  
             1-2 × 105 G3K cells were seeded on a glass coverslip in a six-well tissue culture 
plate. After the culture reaches confluence, the cells were washed 3 times with ice-cold 
PBS and fixed with acetone/methanol (1:1) at room temperature for 15 min and 
incubated with blocking solution (3% bovine serum albumin in PBS) for 1 h. The cells 
were then probed with primary antibody YAP1 (1:200) for 2 hrs followed by incubation 
with FITC-conjugated goat anti-rabbit IgG F(ab′)2fragment (Sigma) (1:1000 dilution) for 
30 min. After being washed 3 times with blocking solution, the cells were re-probed 
with another primary antibody 14-3-3σ (1:50) for 2 hrs followed by incubation with 
Alexa Fluor 647 dye (Life Technologies) for additional 30 min. Then, after being washed 
3 times, the cell nucleus was counterstained with DAPI (25 μg/ml) for 20 min. The 
coverslips were then mounted on the slides before viewing with Olympus 2 confocal 
microscope. The laser excitation lines are as follows: 405 nM for DAPI, 488 nM for FITC, 
and 635 nM for Alexa Fluor 647. The image was then virtualized by Olympus Fluoview 
Ver.3.0 viewer (FV10-ASW 3.0 viewer). 
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H. Immunoprecipitation assay 
             Immunoprecipitation was performed as previously described [166]. Briefly, 1mg 
of cell lysates were first pre-cleaned by incubation with 1 μg of normal mouse IgG at 
4 °C for 1 h, then mixed with 150 μL of protein G agarose beads (50% slurry) and 
incubated at 4 °C for 2 hrs followed by centrifugation at 500× g for 5 min. The cleared 
supernatants were split into two equal parts incubated with either normal mouse IgG 
(as a negative control) or incubated with primary antibodies (anti-Flag, anti-YAP1, anti-
pYAP1, or anti-GFP) at 4 °C for 3 h, then each part was mixed with 50 μL of protein G 
agarose beads. After overnight incubation at 4 °C, the reaction was centrifuged to 
collect precipitates which were then washed five times with lysis buffer (50 mM Tris-HCl, 
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) before being subjected to SDS-
PAGE analysis for Western blot analysis. 
I. Chromatin-immunoprecipitation (ChIP) Assay  
             The ChIP assay was performed using ChIP assay kit following manufacturer’s 
instructions. Briefly, chromatin DNA was crosslinked by formaldehyde and sheared by 
sonication in 200 μl of SDS lysis buffer. After centrifugation, dilution, and pre-cleaning, 
the crosslinked protein-DNA complexes were precipitated by overnight incubation with 
the primary antibodies against histone H3, Uhrf1, DNMT1 or without any antibody as a 
negative control. The precipitated DNA was analyzed by PCR using primers 5′-
CTGAACAGGCCGAACGGTATGAAGAC-3′ and 5′-GAATCGATGATGCGCTTCTTGTCATC-3′ (for 
37 
 
CpG island sequences of 14-3-3σ) and (5′-GCTCTTGGCTAGGTAACTGGACTCTTG-3′ and 5′- 
AGGGGCTTTCCTCATTCTGCCTGCTAC-3′ (for nonCpG island sequences of 14-3-3σ). 
J. Genomic DNA isolation, bisulfite modification, methylation-specific PCR and 
sequencing 
             Genomic DNA was isolated from MiaPaca-2, G3K, and G3KRev cells using Qiagen 
Blood and Cell Culture DNA Kit and modified by sodium bisulfite using the CpGenome 
universal DNA modification kit according to the supplier's protocol, followed by 
Methylation-specific PCR as previously described [167]. Briefly, 10 μg bisulfite-modified 
genomic DNAs were subjected to PCR analysis using primers 5′-
TGGTAGTTTTTATGAAAGGCGTC-3′ and 5′-CCTCTAACCGCCCACCACG-3′ for methylated 
sequence or primers 5′-ATGGTAGTTTTTATGAAAGGTGTT-3′ and 5′-
CCCTCTAACCACCCACCACA-3′ for unmethylated sequence. The PCR products were then 
subjected to separation and analysis by agarose gel electrophoresis. 
             For sodium bisulfite sequencing, 10 μg bisulfite-modified genomic DNAs were 
first amplified using primers 5′-GAGAGAGTTAGTTTGATTTAGAAG-3′ and 5′-
CTTACTAATATCCATAACCTCC-3′ (for 14-3-3σ gene) or primers 5′- 
TGAGTTTTTATAGGTTTAATTAGGAGGG-3′ and 5′-ACTCTCCCCAAACTTCCTACATACTA-3′ 
(for PDGFD gene) and subcloned into pGEM-T vectors (Promega). For sodium bisulfite 
sequencing of 14-3-3σ gene, six independent clones from MiaPaca-2 cells and 4 
independent clones from G3K cells were isolated and subjected to DNA sequencing. For 
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sodium bisulfite sequencing of PDGFD gene, four independent clones from MiaPaca-2, 
G3K, and G3KRev cells were isolated and subjected to DNA sequencing. 
K. Reduced representation bisulfite sequencing (RRBS) and data analysis 
             RRBS was applied on the DNA samples following the protocol described in 
reference [168].  Briefly, genomic DNA was isolated from MiaPaca-2, G3K, and G3KRev 
cells using Qiagen Blood and Cell Culture DNA Kit, respectively. For each cell line, three 
different DNA preparations were diluted to the same volume and same concentration, 
followed by being mixed together to reduce preparation bias and sent to BGI (Beijing 
Genomics Institute) for sequencing. Briefly, the DNA samples were treated with 
restriction enzyme MspI, and Illumina Paired-End protocol was used to construct the 
library following the digestion. 40-220bp fragments were selected and subjected to 
bisulfite treatment by ZYMO EZ DNA Methylation-Gold kit. All the bisulfite converted 
products were amplified by PCR and then followed by sequencing with IlluminaGAII.  
             The RRBS data was analysed in collaboration with Dr. Yunlong-Liu’s lab. Briefly, 
the raw 49bp reads from sequencing were filtered before alignment, in which step the 
adapter sequences, contamination and low quality reads were removed. The cleaned 
reads were subjected to alignment to the genome using BGI SOAPaligner version2.01 
[169]. Due to the strand specificity of DNA methylation, each bisulfite converted read 
pair were aligned twice: (1) the observed cytosines on the forward read of the pair were 
in silico converted to thymines and mapped to the genome converted the same way, 
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and (2) the observed guanines on the reverse read of the pair were in silico converted to 
adenosines and mapped to the genome converted the same way. To estimate 
methylation level for each region, only bases with quality >14 were considered to 
exclude sequencing errors. The level estimation is derived by dividing the number of 
converted cytosine bases in the region by the total number of bases covering CpG 
cytosines in the same region. Differentially methylated regions (DMR) were derived 
from windows with at least 5 CpG sites and a 2-fold change in methylation level, and 
also with Fisher’s exact test p value <0.01, as described in [170].  
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Results 
Section I: Detailed mechanism of reversible epigenetic regulation of 14-3-3σ during 
gemcitabine selection 
A. A gemcitabine-selected pancreatic cancer cell line is cross-resistant to Ara-C but not 
to other anticancer drugs.  
             To investigate acquired gemcitabine resistance, I subjected the pancreatic ductal 
adenocarcinoma cell line MiaPaca-2 to stepwise selection with escalating 
concentrations of gemcitabine starting at 4 nM. The final resistant cells were cloned and 
named G3K that was viable in the presence of 3000 nM of gemcitabine. Authentication 
using short tandem repeat sequence analysis confirms that G3K was derived from the 
parental MiaPaca-2 cells (data not shown). The G3K clone has an estimated IC50 of 
26.6±3.8 µM while the parental MiaPaca-2 cells have an IC50 of 4.1±1.3 nM to 
gemcitabine (Figure 4A-B). Thus, G3K cells are ~6,500 (relative resistance factor or RRF) 
fold more resistant to gemcitabine than the parental MiaPaca-2 cells.  
             The G3K cells were next examined for cross-resistant to gemcitabine analogue, 
Ara-C, and other anticancer drugs using MTT assay. As expected, G3K cells are ~3,500 
fold more resistant to Ara-C with an IC50 of 388.4±48.9 µM than the parental MiaPaca-2 
cells with an IC50 of 112.8±74.4 nM (Figure 4B). However, G3K cells did not show any 
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significant resistance to vinblastine, paclitaxel, and nocodazole although G3K may be 
slightly more resistant to 5-FU and mitoxantrone than MiaPaca-2 cells (Figure 4C). 
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Figure 4. Drug response profiles of MiaPaca-2 and its derivative G3K cells. (A). Dose 
response of MiaPaca-2 and G3K cells to gemcitabine treatment. (B) and (C). IC50 of 
MiaPaca-2 and G3K cells to gemcitabine, Ara-C, 5-FU, mitoxantrone, vinblastine, 
paclitaxel, and nocodazole (n=4-8, **p<0.01, ***p<0.001). 
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B. Ribonucleotide reductase and 14-3-3σ are up-regulated in G3K cells.  
             The finding that G3K cells are cross-resistant to Ara-C but lack of cross-resistance 
to multiple other anticancer drugs prompted us to investigate if any known mechanisms 
of gemcitabine resistance are up-regulated in G3K cells. These mechanisms include but 
are not limited to over-expression of hENT1, ribonucleotide reductase RRM1 and RRM2 
[25, 30, 171]. The expression level of 14-3-3σ was also examined because of its 
association with intrinsic gemcitabine resistance [46]. As shown in Figure 5A, the protein 
level of hENT1 in G3K cells remains the same as in MiaPaca-2 cells, as determined by 
Western blot analysis. However, the expression of RRM1, RRM2, and 14-3-3σ are 
drastically up-regulated in G3K cells compared with the parental MiaPaca-2 cells. 
Interestingly, the other members of the 14-3-3 protein family, 14-3-3θ and 14-3-3ζ, did 
not increase in expression in the G3K cells. 
             To further validate the increased expression of RRM and 14-3-3σ, I next 
performed real time RT-PCR analysis. As shown in Figure 5B, the mRNA levels of both 
RRM1 and 14-3-3σ are significantly increased in G3K cells compared to MiaPaca-2 cells, 
up to ~3.1 fold and ~8.3 fold increase respectively. I also found that the expression of 
RRM1 and 14-3-3σ were up-regulated early during the selection process by testing the 
MiaPaca-2 cells with intermediate level of resistance generated during stepwise 
selections (Figure 5C). Although RRM1 remained in the same up-regulated level in all 
intermediate cells and the final G3K cells, 14-3-3σ appears to be further up-regulated in 
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G3K cells compared to the other preceding intermediate cells. This observation suggests 
that up-regulation of both RRM1 and 14-3-3σ may occur as an early event of acquired 
gemcitabine resistance.  
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Figure 5. Ribonucleotide reductase and 14-3-3σ are up-regulated in G3K cells. (A) 
Western blot analysis of hENT1, RRM1 and 2, 14-3-3σ, ζ, and θ expression in both 
MiaPaca-2 and G3K cells. (B) Real time RT-PCR analysis of RRM1 and 14-3-3σ mRNA in 
MiaPaca-2 and G3K cells (N=3, p<0.001). (C) Western blot analysis of RRM1 and 14-3-3σ 
in the intermediate gemcitabine-resistant cells G100, G500, and G1K. Beta-actin was 
used as a loading control for Western blot analyses and GAPDH was used as an internal 
control for PCR analyses. 
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C. 14-3-3σ over-expression contributes to acquired gemcitabine resistance.  
             Because RRMs are well known contributors to acquired gemcitabine resistance 
[25, 30, 171], I chose to further investigate the potential contribution of 14-3-3σ to the 
acquired gemcitabine resistance in G3K cells. Although 14-3-3σ has been suggested to 
contribute to intrinsic gemcitabine resistance [46] and high 14-3-3σ levels correlate with 
resistance, there are no studies on its potential role in acquired gemcitabine resistance. 
For this purpose, I first knocked down the expression of 14-3-3σ in G3K cells using siRNA 
and tested if 14-3-3σ was involved in gemcitabine and Ara-C resistance in G3K cells. As 
shown in Figure 6B, 14-3-3σ was successfully knocked down in G3K cells by siRNA and 
the reduced 14-3-3σ expression was accompanied with ~80% reduction in gemcitabine 
resistance. Ara-C resistance was also reduced by ~65% by 14-3-3σ knockdown. Thus, 14-
3-3σ over-expression in G3K cells may contribute to both gemcitabine and Ara-C 
resistance.  
             To further verify the role of 14-3-3σ in acquired gemcitabine resistance, I 
established a stable MiaPaca-2 cell line with over-expression of ectopic 14-3-3σ. Figure 
6C shows the stable over-expression of ectopic 14-3-3σ in MiaPaca-2 cells and the 
significantly increased resistance of the stable cells to both gemcitabine and Ara-C, with 
~2.2 fold and ~1.5 fold increase respectively, confirming that 14-3-3σ over-expression 
causes gemcitabine and Ara-C resistance.  
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             To validate the role of 14-3-3σ in acquired gemcitabine resistance in G3K cells, I 
created a partially revertant cell line, G3KRev, by continuously culturing G3K cells in the 
absence of gemcitabine selection for 6 months and tested the level of gemcitabine 
resistance and 14-3-3σ expression. As shown in Figure 6A, G3KRev cells have a 
significantly lower IC50 to gemcitabine than the G3K cells (14.6±1.8 µM vs 22.7±1.1 µM). 
The expression level of 14-3-3σ in the G3KRev cells is also reduced compared with that 
of the G3K cells. Taken together, I conclude that the up-regulated 14-3-3σ likely 
contributes to the acquired gemcitabine resistance in G3K cells and that both the up-
regulated 14-3-3σ expression and gemcitabine resistance are partially reversible in vitro. 
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Figure 6. 14-3-3σ up-regulation contributes to gemcitabine and Ara-C resistance. (A) 
Association of 14-3-3σ expression with gemcitabine resistance. Expression of 14-3-3σ 
and IC50 to gemcitabine in MiaPaca-2, G3K and the revertant G3KRev cells were 
determined using Western blot analysis and MTT assay, respectively. (N=4, **p<0.01). 
(B) 14-3-3σ knockdown reduces gemcitabine and Ara-C resistance in G3K cells. G3K cells 
were transiently transfected with 14-3-3σ siRNA (Si) or scrambled control siRNA (Scr) 
followed by Western blot analysis of 14-3-3σ expression and MTT analysis of cellular 
response to gemcitabine and Ara-C. RRF, relative resistance factor=IC50(Si or 14-3-3σ)/IC50(Scr 
or Vec), (N=3-4, ***p<0.001). (C) 14-3-3σ over-expression in MiaPaca-2 cells causes 
gemcitabine and Ara-C resistance. Stable MiaPaca-2 cells with 14-3-3σ over-expression 
(flag-σ(6)) or transfected with vector control (Vec(1)) were established and subjected to 
Western blot analysis and MTT analysis of cellular response to gemcitabine and Ara-C. 
(N=3-4, ***p<0.001). 
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Figure 6 (cont). 
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D. Differential methylation of 14-3-3σ gene in MiaPaca-2 and G3K cells.  
             The 14-3-3σ gene was found frequently hypermethylated and thus its expression 
was suppressed in several cancer cells [54, 98, 101-104]. Thus, I hypothesize that the 14-
3-3σ gene in the parental MiaPaca-2 cells may be hypermethylated and 14-3-3σ 
expression remains low.  Following gemcitabine selection the methylation status of the 
14-3-3σ gene may be altered, resulting in increased transcription and expression of 14-
3-3σ. To test this hypothesis, I first treated the parental MiaPaca-2 cells with a well-
known demethylating agent, 5-aza-2'-deoxycytidine (5-Aza-dC, decitabine) that inhibits 
DNA methyltransferases, and determined 14-3-3σ expression level using Western blot. 
As shown in Figure 7A, 5-Aza-dC treatment increased 14-3-3σ expression in a dose-
dependent manner. Thus, the 14-3-3σ gene is likely silenced in the parental MiaPaca-2 
cells by methylation and reactivated in G3K cells.  
             Although it has been reported that gemcitabine does not possess the 
pyrimindine ring modification at position 5, which is responsible for inhibition of DNA 
methyltransferases (DNMTs) and, thus, do not inhibit DNA methylation [172], a recent 
study showed that gemcitabine reactivated several epigenetically silenced genes 
possibly by inhibiting DNMT1 [173]. Thus, it is possible that treatment with gemcitabine 
during selection reactivated 14-3-3σ gene expression. To test this possibility, I treated 
the parental MiaPaca-2 cells with different concentrations of gemcitabine followed by 
Western blot analysis of 14-3-3σ expression. As shown in Figure 7A, unlike 5-Aza-dC, 
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gemcitabine treatment did not increase 14-3-3σ expression. Thus, reactivation of 14-3-
3σ gene in G3K cells is unlikely due to direct gemcitabine-induced demethylation.  
             Next, I compared the methylation status of the 14-3-3σ gene in G3K and the 
parental MiaPaca-2 cells using methylation-specific PCR (MSP). As shown in Figure 7B, 
14-3-3σ gene in the parental MiaPaca-2 cells was amplified only by primers for 
methylated sequences whereas in G3K cells it was amplified only by primers for 
unmethylated sequences. Thus, the 14-3-3σ gene in the parental MiaPaca-2 cells is 
heavily methylated whereas it is unmethylated in G3K cells. Analysis of the first exon 
with 27 CpG dinucleotides in the 14-3-3σ gene that are known to be methylated in 
cancer cells [54] using sodium bisulfite sequencing shows that 25 of these CpG 
dinucleotides in the parental MiaPaca-2 cells are fully methylated and the remaining 2 
are partially methylated (Figure 7C). However, in G3K cells 23 of the 27 CpG 
dinucleotides are unmethylated and the remaining 4 are partially methylated. Clearly, 
the methylations of the 14-3-3σ gene in the parental MiaPaca-2 cells have been 
removed in G3K cells. 
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Figure 7. Methylation status of 14-3-3σ gene in MiaPaca-2 and G3K cells. (A) Effect of 
5-Aza-dC or gemcitabine treatment on 14-3-3σ expression. MiaPaca-2 cells were treated 
with increasing concentrations of 5-Aza-dC or gemcitabine for 5 days or 72hrs 
respectively, followed by Western blot analysis of 14-3-3σ, cleaved Parp-1 and actin as a 
loading control. (B) Methylation-specific PCR (MSP) analysis of MiaPaCa-2 and G3K cells. 
Con., control MSP without genomic DNA input. (C) Sodium bisulfite sequencing analysis 
of MiaPaCa-2 and G3K cells. The 27 CpG islands in the first exon of 14-3-3σ gene is 
shown with solid circles for fully methylated, open circles for unmethylated, and half 
filled circles for partially methylated CpG dinucleotides. The sequence profile containing 
CpG dinucleotides #10-14 is shown for both MiaPaca-2 and G3K cells. (D) Methylation 
status of 14-3-3σ gene in the revertant G3KRev cells. MSP were used to determine the 
methylation status of 14-3-3σ gene in G3KRev cells as with MiaPaca-2 and G3K cells as 
controls. U, primers for unmethylated; M, primers for methylated. 
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Figure 7 (cont). 
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E. Demethylation of the 14-3-3σ gene is reversible.  
             As shown above, the increased expression of 14-3-3σ in G3K cells is partially 
reversed in the revertant G3KRev cells. The partial reversion in 14-3-3σ expression may 
be due to partial reversal of the methylation status of the 14-3-3σ gene. To test this 
possibility, I performed MSP of isolated genomic DNAs from the partially revertant 
G3KRev cells as described above. Figure 7D shows that the 14-3-3σ gene can be 
amplified by primers for both methylated and unmethylated sequences, indicating that 
the 14-3-3σ gene in G3KRev cells is likely partially reversed and that some cells have 
restored the methylation of their 14-3-3σ gene while others retains the demethylated 
14-3-3σ gene. Thus, demethylation of the 14-3-3σ gene is likely partially reversible. The 
incomplete reversal of 14-3-3σ gene methylation following removal of gemcitabine 
suggests that the increased 14-3-3σ expression in G3K cells is unlikely due to direct 
gemcitabine-induced demethylation, consistent with the observation shown in Figure 
7A. 
             Previously, up-regulation of 14-3-3σ expression was also observed in an 
Adriamycin-selected breast cancer cell line MCF7/AdVp3000 and it was decreased in the 
revertant MCF7/AdVp3000/Rev cells [63] (see also Figure 8A). However, the mechanism 
of 14-3-3σ regulation in these cell lines is not yet known. To determine if gene 
methylation is involved in regulating 14-3-3σ expression in these cells, I performed MSP 
of isolated genomic DNAs from the parental MCF7, Adriamycin-selected 
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MCF7/AdVp3000, and the revertant MCF7/AdVpG3K/Rev cells with MiaPaca-2 cells as a 
positive control. As shown in Figure 8B, while the 14-3-3σ gene in MiaPaca-2 cells can 
be amplified only using primers for methylated sequences, in all breast cancer cells it 
can be amplified only using primers for the unmethylated sequences. Thus, up-
regulation of 14-3-3σ expression in MCF7/AdVp3000 cells and its reversal in 
MCF7/AdVp3000/Rev cells is unlikely due to changes in methylation status of the 14-3-
3σ gene. 
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Figure 8. 14-3-3σ up-regulation in Adriamycin-selected MCF7/AdVp3000 cells is not 
due to gene demethylation. (A) Western blot analysis of 14-3-3σ expression in MCF7, 
MCF7/Advp3000 (AdVp), and MCF7/AdVp/Rev (Rev) cells. Actin was used as a loading 
control. (B) MSP analysis of 14-3-3σ gene in MCF7, MCF7/Advp3000 (AdVp), and 
MCF7/AdVp/Rev (Rev) cells with MiaPaCa-2 cells as a control. U, primers for 
unmethylated; M, primers for methylated. Contl., control MSP without genomic DNA 
input. 
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F. Uhrf1 and DNMT1 play important roles in regulating 14-3-3σ expression.  
             To determine what regulates the reversible methylation of 14-3-3σ gene in 
MiaPaca-2 and G3K cells, I first compared the expression level of enzymes important for 
DNA methylation among the parental MiaPaca-2, gemcitabine resistant G3K, and the 
partially revertant G3KRev cells using Western blot or real-time RT-PCR. As shown in 
Figure 9A, while DNMT3a and DNMT3b were increased in G3K and remained high in 
G3KRev cells, DNMT1 is increased in G3K but reduced back to the basal level in G3KRev 
cells. The expression pattern of these methyltransferases is peculiar and inconsistent 
with the expression pattern of 14-3-3σ in MiaPaca-2, G3K, and G3KRev cells. 
             Another protein of importance in gene methylation, Uhrf1, has been shown to 
play a major role in recruiting DNMTs [174] and loss of Uhrf1 results in 75% reduction in 
genomic methylation [175]. Thus, I tested the expression pattern of Uhrf1. As shown in 
Figure 9A, Uhrf1 protein is reduced in G3K cells and increased in the G3KRev cells. The 
profile of Uhrf1 expression in these cells is consistent with the partially reversible 
change in 14-3-3σ expression and gene methylation in these cells. The consequence of 
Uhrf1 binding is recruitment of DNMT1 and histone deacetylase 1, resulting in 
methylation of newly synthesized DNA strands [124, 126-128]. Thus, reduced Uhrf1 
expression in G3K cells is likely responsible for reduced methylation of 14-3-3σ gene by 
reducing recruitment of DNMT1 protein to the methylated CpG islands despite the 
presence of high level of DNMT1. In MiaPaca-2 cells, however, the high level of Uhrf1 
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may efficiently recruit enough DNMT1 despite low DNMT1 level for efficient 
methylation of 14-3-3σ gene. If so, knocking down either Uhrf1 or DNMT1 in MiaPaca-2 
cells would effectively reduce the level of the recruiter (Uhrf1) or the pool of DNMT1 to 
be recruited for methylation of 14-3-3σ gene and consequently increase 14-3-3σ 
expression. Furthermore, the slight increase of Uhrf1 expression in the G3KRev cells 
may be responsible for the increased methylation and reduced expression of 14-3-3σ 
gene. In addition, due to the fact that Uhrf1 has been shown to regulate p21 expression 
[132], I next tested the expression of p21 in MiaPaca-2, G3K, and G3KRev cells. As 
shown in Figure 9A, p21 protein level shows an expression profile in these cells similar 
to that of 14-3-3σ, consistent with the possible regulatory role of Uhrf1 in these cells. 
             To determine if the reduced Uhrf1 expression is possibly responsible for 
increased expression of the 14-3-3σ gene in G3K cells, I knocked down Uhrf1 in the 
parental MiaPaca-2 cells using siRNA and tested its effect on 14-3-3σ expression. Figure 
9B shows that 14-3-3σ protein level is dramatically increased by Uhrf1 knockdown. This 
observation is confirmed by real time RT-PCR analysis of 14-3-3σ mRNA, with ~1.4 fold 
and ~2.4 fold increase of 14-3-3σ mRNA by Uhrf1 and DNMT1 knockdown, respectively 
(Figure 9C).  
             To determine if DNMTs also contribute to 14-3-3σ expression regulation, I 
performed similar experiment by knocking down DNMT1, DNMT3a, and DNMT3b in 
MiaPaca-2 cells. Figure 9D shows successful knockdown of DNMT1, DNMT3a, and 
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DNMT3b as determined using Western blot or real-time RT-PCR. However, only DNMT1 
knockdown significantly up-regulated the protein level of 14-3-3σ. DNMT3a and 
DNMT3b knockdown did not appear to affect 14-3-3σ expression. The effect of DNMT1 
knockdown on 14-3-3σ expression was also confirmed by real time RT-PCR analysis 
(Figure 9C). Taken together, I conclude that likely both Uhrf1 and DNMT1 play 
important roles in regulating 14-3-3σ expression. 
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Figure 9. Role of Uhrf1 and DNMT1 in 14-3-3σ expression. (A) Western blot analysis of 
Uhrf1, DNMT1, DNMT3a, and p21 expression as well as real-time RT-PCR analysis of 
DNMT3b expression in MiaPaca-2, G3K, and G3KRev cells. (B-D) Effect of Uhrf1, DNMT1, 
DNMT3a and DNMT3b knockdown on 14-3-3σ expression. MiaPaca-2 cells were 
transiently transfected with scrambled control siRNA (Scr) or siRNAs targeting Uhrf1 (B), 
DNMT1, DNMT3a, and DNMT3b (D) followed by Western blot analysis of Uhrf1, DNMT1, 
DNMT3a, and 14-3-3σ protein levels (B, D) or real time RT-PCR analysis of DNMT3b and 
14-3-3σ mRNA levels (C-D). (N=4-5, *p<0.05, ***p<0.001). Actin and GAPDH were used 
as a loading control for Western blot and internal control for PCR analyses, respectively. 
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Figure 9 (cont). 
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G. Uhrf1 binds and helps recruit DNMT1 to methylated region of 14-3-3σ gene. 
             To further determine the role of Uhrf1 and DNMT1 in regulating 14-3-3σ 
expression and gene methylation, I first determined if Uhrf1 binds to the methylated 
CpG islands in the first exon of 14-3-3σ gene in MiaPaca-2 cells using ChIP assay. As 
shown in Figure 10A, Uhrf1 was bound to the CpG islands but not to the CpG-free 
sequences in the promoter region of the 14-3-3σ gene in MiaPaca-2 cells. Knocking 
down Uhrf1 also reduced Uhrf1 binding to the CpG islands of 14-3-3σ gene (Figure 10B). 
Thus, Uhrf1 likely can bind to the methylated CpG island sequences of the 14-3-3σ gene. 
             As shown in Figure 9A, DNMT1 expression was found increased in G3K cells, 
which is peculiar since methylation of 14-3-3σ gene in G3K cells is reduced. However, 
because Uhrf1 binding to CpG island sequences helps recruit DNMT1 to maintain the 
methylation status of the DNA, it is possible that the reduced Uhrf1 expression in G3K 
cells reduces DNMT1 recruitment despite the higher level of DNMT1 in G3K cells. To test 
this possibility, I first compared the binding of DNMT1 to the CpG island sequences of 
the 14-3-3σ gene between MiaPaca-2 and G3K cells. As shown in Figure 10C, binding of 
DNMT1 to the CpG island sequences of 14-3-3σ gene is indeed much less in G3K than in 
MiaPaca-2 cells despite the higher expression level of DNMT1 in G3K cells. Importantly, 
Uhrf1 knockdown in MiaPaca-2 cells dramatically reduced DNMT1 binding to the CpG 
island sequences of the 14-3-3σ gene (Figure 10D), indicating that DNMT1 could not be 
effectively recruited to the CpG island sequences of the 14-3-3σ gene in the absence of 
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Uhrf1, and hence Uhrf1 is the recruiter of DNMT1. Thus, I conclude that Uhrf1 likely 
plays a major role in regulating 14-3-3σ expression by binding to its CpG-rich sequences 
and helps recruit DNMT1 to the site to reversibly methylate the 14-3-3σ gene during 
replication. The reduced Uhrf1 expression by gemcitabine selection in G3K cells likely 
decreased DNMT1 recruitment and methylation of 14-3-3σ gene while the slightly 
increase in Uhrf1 level in G3KRev cells is responsible for partial reversal of 14-3-3σ gene 
methylation. 
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Figure 10. Binding of Uhrf1 and DNMT1 to the CpG islands of the 14-3-3σ gene. (A) 
ChIP analysis of Uhrf1 binding to the CpG island sequences or nonCpG island 
sequences of 14-3-3σ gene. (B, D) Effect of Uhrf1 knockdown on Uhrf1 and DNMT1 
binding to the CpG island sequences of 14-3-3σ gene in MiaPaca-2 cells. MiaPaca-2 cells 
were transiently transfected with scrambled control or Uhrf1 siRNAs followed by ChIP 
analysis of Uhrf1 and DNMT1 binding. (C) DNMT1 binding to the CpG island sequence of 
14-3-3σ gene in G3K cells is less than that in MiaPaca-2 cells. ChIP with histone H3 
antibody or without any primary antibody were used as positive and negative controls, 
respectively. Normal IgG was also used as negative control, which did not 
immunoprecipitate any DNA (data not shown). 
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H. Gemcitabine treatment does not affect Uhrf1 and DNMT1 expression.  
             Finally, to investigate if the altered expression of Uhrf1 and DNMT1 in G3K cells 
is potentially due to gemcitabine treatments during selection, I performed a Western 
blot analysis to detect both Uhrf1 and DNMT1 expression in MiaPaca-2 cells following 
treatments with gemcitabine at different concentrations for 72 hrs. As shown in Figure 
11, gemcitabine treatments had no effect on Uhrf1 and DNMT1 expression. Therefore, 
the mechanism of regulation of Uhrf1 and DNMT1 expression in the drug resistant cells 
remains to be determined. 
             Overall, this section of my thesis demonstrated that 14-3-3σ over-expression 
contributed to acquired gemcitabine resistance and that the up-regulated 14-3-3σ 
expression was caused by lack of gene methylation regulation during gemcitabine 
selection. As summarized in Figure 12, Uhrf1 and DNMT1 bind to the methylated region 
of 14-3-3σ gene in parental MiaPaca-2 cells to maintain the methylation status, whereas 
during gemcitabine selection, the expression of Uhrf1 is dramatically decreased and 
thus insufficient to recruit DNMT1 to the site to methylate the DNA, resulting in 14-3-3σ 
gene demethylation and re-expression. After gemcitabine removal, however, the slight 
increase of Uhrf1 expression likely functions to recruit the methylation machinery to 
restore the methylation of 14-3-3σ gene. 
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Figure 11. Effect of gemcitabine treatment on Uhrf1 and DNMT1 expression. MiaPaca-
2 were treated with/without increasing concentrations of gemcitabine, and G3K cells 
were used as control without treatment, followed by Western blot analysis of Uhrf1, 
DNMT1. Actin was used as a loading control. 
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Figure 12. Schematic model of epigenetic regulation of 14-3-3σ gene following 
gemcitabine selection and drug removal. The relative expression levels of Uhrf1 and 
DNMT1, as well as their binding status to 14-3-3σ gene during gemcitabine selection or 
drug removal are shown in the model. Solid circles represent fully methylated CpG 
islands of 14-3-3σ gene, and open circles represent unmethylated CpGs. 
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Section II: Identification of PDGFD as a potential contributor to acquired gemcitabine 
resistance by Reduced Representation Bisulfite Sequencing (RRBS) 
A. Identification of reversibly-methylated genes using Reduced Representation 
Bisulfite Sequencing (RRBS).  
             The finding of demethylation of the 14-3-3σ gene in gemcitabine resistant cells 
led to a hypothesis that other genes may also have changed epigenetically following 
gemcitabine selection. To profile global changes in gene methylation in response to 
gemcitabine selection, genomic DNAs from MiaPaca-2, G3K, and G3KRev cells were 
isolated and subjected to RRBS sequencing, which yield genome-
wide methylation profiles on a single nucleotide level, by BGI (Beijing Genomics 
Institute). The RRBS data were analysed in collaboration with Dr. Yunlong-Liu’s lab. 
             As a result, the RRBS yields about 65~70 Million clean reads for each sample, 
with map rate of >92%, unique mapping rate of >70%, and >97% of unique reads with 
enzyme cutting site (Figure 13A). Moreover, the RRBS targeted a reasonable proportion 
of genome of interest in all samples, with >70% of promoters and >83% of CG islands 
were covered respectively (Figure 13B). The individual CpG sites within CG islands and 
promoters were also examined and good depth coverage at 4X and 10X were achieved, 
and all samples showed consistent coverage (data not shown). 
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Figure 13. RRBS sequencing results comparison and characterization of genomic 
coverage. (A) RRBS sequencing results comparison. (B) Genomic coverage 
characterization of promoter and CG island (CGI) numbers. 
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             According to RRBS outcome, 845 genes are differentially methylated between 
MiaPaca-2 and G3K cells, and 282 genes are differentially methylated between G3K and 
G3KRev cells. The list of these differentially methylated genes is shown in Appendices. 
Because the methylation changes in the promoter region most likely influence gene 
transcription and expression, I filtered these genes with differential methylation level in 
the promoter region and with a 2-fold change cutoff. As shown in Figure 14, 159 genes 
have increased methylation while 459 genes have decreased methylation in G3K cells 
compared with MiaPaca-2 cells. By comparing with G3K cells, G3KRev cells have 104 
genes with increased and 88 genes with decreased methylation. Together, there are 65 
genes that have reversible methylation changes from MiaPaca-2 to G3K and to G3KRev 
cells (Table 2). 
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Figure 14. Flowchart of DMR filteration of genes. Genes with DMR p-value<0.01 were 
first filtered by DMR at the promoter regions, followed by further filter with 2-fold 
methylation level change. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
72 
 
Table 2. List of reversibly methylated genes. 
Paca2 vs G3K up, G3K vs G3KRev down Paca2 vs G3K down, G3K vs G3KRev up 
ADORA2B, CDC42EP3, CPNE7, FBXO27, 
JAG2, MIR1915, MRPS6, NPAS2, OLIG1, 
PTPRG, PWWP2B,  SLC45A1, SNORD56B, 
SOX13, TNRC18, WNT9A 
AFAP1L2, ANXA2P3, APBA1, CCNO, 
CDC42BPB, CDK6, CHRNA7, CRAMP1L, 
DDIT4L, DSE, DUSP6, EFNA5, ELOVL2-AS1, 
FAM133B, FRAS1, FUOM, GALNT7, GNS, 
GRM4, H2AFY2, JMJD8, KIAA1324L, 
KIF21B, LOC100506190, LONRF3, MCTP1, 
MDFIC, MIR205HG, MMP25, MTA1, NKX1-
2, PDGFD, PRDM1, RAET1G, RASD2, 
RNASET2, SEMA5B, SLC25A27, SLC31A2, 
SLC35D3, SOWAHD, TMEM181, TRPC3, 
WDR1, WNT11, ZNF593, ZNF669, ZNF808, 
ZNF83 
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             Among these 65 genes, 10 genes with the highest degree of methylation level 
change were selected for further analysis using real-time RT-PCR. Figure 15 shows that 
the mRNA level of five genes (CDK6, SLC35D3, SLC25A27, PDGFD, and TRPC3) with 
decreased methylation increases in G3K cells compared with MiaPaca-2 cells.  However, 
the other genes have different outcomes. While the mRNA level of DUSP6 with 
decreased methylation is reduced, the mRNAs of Olig1 and PTPRG with increased 
methylation are significantly increased and the mRNAs of Cdc42EP3 and Adora2B with 
increased methylation were not significantly affected in G3K cells (Table 3). Therefore, 
the methylation change of the genes in the promoter region may not be sufficient to 
predict change in the mRNA level of corresponding genes.  
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Figure 15. Identification of transcriptional changes in candidate genes. (A-B) Real time 
RT-PCR analysis of mRNA level of candidate genes including DUSP6, Olig1, Cdc42EP3, 
Adora2B, PTPRG, CDK6, SLC35D3, SLC25A27, PDGFD, and TRPC3 gene between 
MiaPaca-2 and G3K cells. GAPDH was used as internal control. (N=3-5, *p<0.05, 
**p<0.01, ***p<0.001). ↑: methylation is increased in G3K cells, ↓: methylation is 
decreased in G3K cells. 
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Table 3. Identification and characterization of candidate genes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
DMR (G3K-
MiaPaca-2)  
mRNA level change 
(G3K/MiaPaca-2) Significance 
Negative correlation of methylation change with mRNA level change  
CDK6  -0.5 1.684548 p<0.001 
SLC35D3  -0.57 2.171952 p<0.05 
SLC25A27  -0.39 2.566402 p<0.05 
PDGFD  -0.41 6.164361 p<0.05 
TRPC3  -0.48 15.42079 p<0.001 
Positive correlation of methylation change with mRNA level change  
PTPRG  0.21 1.551086 p<0.01 
Olig1  0.34 4.334516 p<0.001 
DUSP6  -0.41 0.596951 p<0.01 
No correlation of methylation change with mRNA level change  
cdc42EP3  0.28 1.074495 NS 
Adora2B  0.26 1.148135 NS 
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B. Reversible up-regulation of PDGFD.  
             Next, TRPC3 and PDGFD were selected for validation of their expression at 
protein level. Firstly, membrane fractions were prepared from both MiaPaca-2 and G3K 
cells for Western blot analysis of TRPC3. As shown in Figure 16A, TRPC3 protein level did 
not appear to change despite its mRNA level increased ~15 fold in G3K cells. Thus, 
TRPC3 mRNA level does not seem to correlate with its protein level. To determine 
PDGFD protein level, MiaPaca-2 and G3K cells were cultured in serum-free medium for 
24 hrs, followed by collection of conditioned medium (CM) and TCA precipitation. The 
precipitated proteins were subjected to Western blot analysis. As shown in Figure 16C, 
PDGFD production was dramatically elevated in G3K cells compared with MiaPaca-2 
cells.  
             To determine if increased PDGFD production in G3K cells was reversed in G3KRev 
cells, real-time RT-PCR analysis was performed. As shown in Figure 17A, the increased 
PDGFD mRNA level in G3K cells (~16 fold increase compared with MiaPaca-2 cells) was 
dramatically decreased in the G3KRev cells (only ~2.4 fold increase compared with 
MiaPaca-2 cells). Moreover, the Western blot analysis confirmed this finding (Figure 
17C). Thus, the expression of PDGFD is reversibly up-regulated in G3K cells.  
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Figure 16. Identification of TRPC3 and PDGFD expression in MiaPaca-2 and G3K cells. 
(A) Western blot detection the expression level of TRPC3 protein in the cell membrane 
fraction. MRP3 was used as a loading control for membrane fraction. (B) The secreted 
proteins in MiaPaca-2 and G3K conditioned medium (CM) were precipitated by TCA 
precipitation method, followed by SDS-PAGD and coomassie blue staining. (C) The 
secretion of PDGFD is significantly increased in G3K cells. The secreted proteins in 
MiaPaca-2 and G3K conditioned medium (CM) were precipitated by TCA precipitation 
method, followed by Western blot detection of the expression of PDGFD. 
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Figure 17. Reversible transcription and expression of PDGFD. (A) Real time RT-PCR 
analysis of PDGFD mRNA level in MiaPaca-2, G3K, and G3KRev cells. GAPDH was used as 
internal control. (N=4, **p<0.01). (B) The secreted proteins in MiaPaca-2, G3K, and 
G3KRev conditioned medium (CM) were precipitated by TCA precipitation method, 
followed by SDS-PAGD and coomassie blue staining. (C) PDGFD expression is reversibly 
increased in G3K cells. The secreted proteins in MiaPaca-2, G3K, and G3KRev 
conditioned medium (CM) were precipitated by TCA precipitation method, followed by 
Western blot detection of PDGFD expression. 
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C. Validation of reversible methylation change of PDGFD gene.  
             To validate the RRBS data that suggest a reversible methylation change of PDGFD 
gene in G3K cells, I performed sodium-bisulfite gene sequencing analysis of the 26 CpG 
dinucleotides residing in the promoter region of PDGFD gene in all three cell lines. As 
shown in Figure 18, 14-22 out of 26 CpG dinucleotides were methylated in MiaPaca-2 
cells. However, these CpG dinucleotides were all unmethylated in G3K cells. 
Interestingly, in G3KRev cells, 16-17 out of 26 CpG dinucleotides were again methylated. 
Thus, the methylation change of PDGFD promoter is reversible, and consistent with 
RRBS data. 
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Figure 18. Reversible methylation change of PDGFD gene. Sodium bisulfite sequencing 
analysis of PDGFD gene in MiaPaca-2, G3K, and G3KRev cells was conducted. Briefly, 
genomic DNA was treated with sodium bisulfite and the promoter region of PDGFD 
gene was amplified by PCR, followed by cloning into pGEM-T vector. 4 clones from 
each cell line were picked for sequencing. The 26 CpG islands in promoter region of 
PDGFD gene were shown with solid circles for fully methylated, open circles for 
unmethylated. The chromatogram represents sequence profile containing CpG 
dinucleotides #2-13 for all three cells. 
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Figure 18 (cont). 
82 
 
D. PDGFD up-regulation plays an important role in gemcitabine resistance.  
             It has been reported that PDGFD signaling is frequently deregulated in human 
malignancies with up-regulated expression in prostate, lung, renal, ovarian, brain, and 
pancreatic cancer [146, 147, 149-152]. However, its relationship with therapeutic drug 
resistance is limited to the discovery of its role in regulation of radiosensitivity in 
prostate adenocarcinoma, as well as its influence on sensitivity and resistance of 
glioblastoma to semustine [154, 158]. To determine if PDGFD potentially contributes to 
gemcitabine resistance in pancreatic cancer, I knocked down PDGFD in both G3K and 
Aspc-1 cells and performed the MTT assay to test its response to gemcitabine. Figure 
19A and Figure 19C show knockdown of PDGFD in G3K and Aspc-1 cells at both protein 
and mRNA levels, respectively. As shown in Figure 19B and Figure 19D, the sufficient 
knockdown of PDGFD is accompanied with a dramatic reduction of gemcitabine 
resistance by 63.7%-76.5% in G3K and 46.4%-84.8% in Aspc-1 cells, respectively. Thus, 
PDGFD knockdown likely reduces gemcitabine resistance in both cells.   
             Next, to further test the influence of PDGFD over-expression on gemcitabine 
sensitivity, stable clones with PDGFD over-expression were generated from MiaPaca-2 
cells. Figure 20A-B show increased PDGFD production in these clones compared with 
vector control clone by Western blot analysis of conditioned medium. Moreover, the 
increased production of PDGFD is accompanied with an increased resistance to 
gemcitabine by 4.8-4.9 fold (Figure 20C). Furthermore, MiaPaca-2 cells cultured in 
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conditioned medium from G3K cells are also more resistant to gemcitabine (by 2.4-fold 
increase averagely), than cells cultured with fresh medium (Figure 20D). Together, these 
results suggest that PDGFD plays an important role in gemcitabine resistance in human 
pancreatic cancers and that there may be bystander effect of resistant cells on sensitive 
cells. 
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Figure 19. PDGFD over-expression contributes to gemcitabine resistance in both G3K 
and Aspc-1 cells. (A, C) Western blot and PCR analysis of PDGFD knockdownin G3K and 
Aspc-1 cells. G3K (A) and Aspc-1 (C) cells were transiently transfected with scrambled 
control siRNA (Scr) or siRNAs targeting PDGFD followed by Western blot analysis of 
secreted PDGFD protein level, and RT-PCR analysis of the PDGFD mRNA level. GAPDH 
was used as an internal control for RT-PCR. (N=5-6, **p<0.01, ***p<0.001). (B, D) 
PDGFD knocking down in G3K and Aspc-1 cells reduces gemcitabine resistance. G3K (B) 
and Aspc-1 (D) cells were transiently transfected with scrambled control siRNA (Scr) or 
siRNAs targeting PDGFD followed by MTT assay for detection of the drug resistance. 
(N=3-4, **p<0.01, ***p<0.001).  
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Figure 20. PDGFD over-expression leads to increased gemcitabine resistance in 
MiaPaca-2 cells. (A-B) MiaPaca-2 cells were stably transfected with vector control 
(vec(1)) or PDGFD plasmid (PD(2) and PD(9)) followed by SDS-PAGE analysis of total 
secreted proteins as a loading control (A) and Western blot analysis of PDGFD 
production (B). (C) PDGFD over-expression increases gemcitabine resistance. MiaPaca-2 
cells were stably transfected with vector control (vec(1)) or PDGFD plasmid (PD(2) and 
PD(9)) followed by MTT assay for detection of gemcitabine resistance. (N=5, *p<0.05). 
(D) Bystander effect of resistant cells on sensitive cells. MiaPaca-2 cells were cultured in 
either fresh medium or G3K conditioned medium, followed by MTT assay for detection 
of gemcitabine resistance. (N=5, **p<0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
86 
 
E. PDGFD over-expression contributes to gemcitabine resistance possibly by regulating 
STAT3 signaling pathway.  
             It has been reported that PDGFD activation triggers a number of downstream 
signaling pathways including activation of phosphatidylinositol 3 kinase (PI3K), Akt, 
nuclear factor-κB (NF-κB), Notch, and extracellular signal-regulated kinase (ERK) [139, 
145-147]. It has also been reported that STAT3 is up-regulated in several drug-selected 
cancer cells including acquired resistance to erlotinib, vemurafenib, temozolomide, 
cisplatin, and paclitaxel [176-180]. Thus, I hypothesize that PDGFD over-expression may 
contribute to gemcitabine resistance by regulating STAT3 signaling pathway.  
             To test this hypothesis, I first compared the activation of STAT3 signaling 
pathway in MiaPaca-2 and G3K cells. As shown in Figure 21A, both the p-stat3 and total 
Stat3 as well as Stat3 downstream targets including VEGF and MMP2 were up-regulated 
in G3K cells. More importantly, knocking down PDGFD in G3K cells led to significant 
reduction of p-stat3/Stat3 and Stat3 downstream targets (Figure 21B). Similarly, 
knocking down PDGFD in Aspc-1 cells also reduced the level of p-stat3 and total Stat3 as 
well as Stat3 downstream targets (data not shown) while over-expression of PDGFD in 
parental MiaPaca-2 cells caused markedly increased level of p-stat3, total Stat3 and 
Stat3 downstream target VEGF (Figure 21C). Interestingly, the revertant G3KRev cells 
showed dramatically decreased expression of p-stat3 to the basal level compared with 
G3K cells although the total Stat3 level seems unchanged (Figure 22C). Taken together, 
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these findings strongly suggest that PDGFD actively regulates STAT3 signaling pathway, 
which may mediate PDGFD-induced gemcitabine resistance in pancreatic cancer cells. 
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Figure 21. PDGFD actively regulates STAT3 signaling pathway. (A) Western blot analysis 
of secreted PDGFD, p-stat3, stat3, VEGF, secreted VEGF, and secreted MMP2 expression 
in both MiaPaca-2 and G3K cells. (B) Effect of PDGFD knockdown on Stat3 signaling in 
G3K cells. G3K cells were transiently transfected with scrambled control siRNA (Scr) or 
siRNAs targeting PDGFD followed by Western blot analysis of p-stat3, stat3, VEGF, and 
MMP2 secretion. Actin was used as a loading control. (C) Effect of PDGFD over-
expression on Stat3 signaling in MiaPaca-2 cells. MiaPaca-2 cells were stably transfected 
with vector control (vec(1)) or PDGFD plasmid (PD(9)) followed by Western blot analysis 
of p-stat3, stat3, and VEGF expression. Actin was used as a loading control.  
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F. Stat3 potentially contributes to gemcitabine resistance.  
             Finally, the potential role of Stat3 in gemcitabine resistance was tested by over-
expressing wild type and constitutively activated mutant Stat3 (Stat3c) in parental 
MiaPaca-2 cells (Figure 22A). Figure 22B shows that over-expressing either the wild type 
or the constitutively activated Stat3 in parental MiaPaca-2 cells significantly increased 
gemcitabine resistance, by ~1.7 fold and ~2.3 fold increase respectively. Therefore, it is 
possible that PDGFD-induced up-regulation of Stat3 signaling may serve as a mediator 
for PDGFD-induced gemcitabine resistance. 
             Thus, I conclude that gemcitabine selection causes PDGFD gene demethylation 
and protein up-regulation, and its over-expression in turn contributes to gemcitabine 
resistance by activating STAT3 signaling pathway (Figure 23). 
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Figure 22. Stat3 over-expression promotes gemcitabine resistance in MiaPaca-2 cells. 
(A-B) Effect of PDGFD over-expression on gemcitabine resistance in MiaPaca-2 cells. 
MiaPaca-2 cells were stably transfected with vector control, stat3, or stat3c plasmid 
followed by Western blot analysis for detecting the expression of stat3 (A) or MTT assay 
for detecting the gemcitabine resistance. Actin was used as a loading control for 
Western blot. (N=3-4, **p<0.01). (C) Western blot detection of the expression of total 
Stat3 and p-stat3 in MiaPaca-2, G3K, and G3KRev cells. Actin was used as a loading 
control. 
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Figure 23. Schematic model of PDGFD-mediated gemcitabine resistance during drug 
selection. Gemcitabine selection leads to PDGFD gene demethylation and protein up-
regulation, which binds to its cognate receptor and activates Stat3 signaling. Activation 
of Stat3 signaling pathway causes transcription of its downstream target genes and 
contributes to gemcitabine resistance. 
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Section III: Molecular mechanism of 14-3-3σ-mediated gemcitabine resistance in 
pancreatic cancer 
             The previous studies showed that 14-3-3σ over-expression in G3K cells 
contribute to gemcitabine resistance. However, the underlying mechanism through 
which 14-3-3σ contributes to acquired gemcitabine resistance remains unknown. Here, 
based on the escalating interest in recent years on one potential binding partner of 14-
3-3σ, YAP1, I tested the hypothesis that 14-3-3σ contributes to acquired gemcitabine 
resistance by binding to YAP1.  
A. YAP1 over-expression in G3K cells and its contribution to gemcitabine resistance. 
             To determine the potential role of YAP1 in 14-3-3σ-mediated gemcitabine 
resistance, I first tested the level of total YAP1 and p-YAP1 in both MiaPaca-2 and G3K 
cells. As shown in Figure 24, the level of both YAP1 and p-YAP1 as well as the mRNA 
level of YAP1 (~4.7 fold increase) were found highly elevated in G3K compared with 
MiaPaca-2 cells, suggesting that YAP1 may be transcriptionally up-regulated in G3K cells. 
Interestingly, 14-3-3σ knockdown in G3K cells also reduced total YAP1, p-YAP1, and 
YAP1 mRNA levels (~50% reduction) (Figure 25A-B). Moreover, over-expression of 14-3-
3σ in MiaPaca-2 cells resulted in an increase of YAP1, p-YAP1, and YAP1 mRNA levels 
(~2.5 fold increase) (Figure 25C-D), indicating that YAP1 may be transcriptionally 
regulated by 14-3-3σ. However, knocking down of YAP1 in G3K cells did not affect the 
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protein level of 14-3-3σ (Figure 26A). Thus, 14-3-3σ may regulate the transcription and 
expression of YAP1, but not vice versa.  
             To determine whether the increased expression of YAP1 in G3K cells contributes 
to gemcitabine resistance, I first knocked down YAP1 in G3K cells by using specific siRNA 
followed by examining the difference in gemcitabine resistance using MTT assay. As 
shown in Figure 26A-B, knocking down YAP1 dramatically reduced the drug resistance in 
G3K cells, by up to 80% reduction. However, over-expression of YAP1 in the parental 
MiaPaca-2 cells did not significantly influence the gemcitabine resistance (Figure 26C-D). 
The reason for the discrepancy between these two experiments could be that YAP1 
over-expression in MiaPaca2 cells may need 14-3-3σ for gemcitabine resistance. To test 
this possibility, I over-expressed YAP1 in MiaPaca-2 cells with stable flag-14-3-3σ-over-
expression and tested the effect on gemcitabine resistance. As shown in Figure 26E-F, 
over-expression of YAP1 in these cells further increase gemcitabine resistance by ~2.4 
fold. Thus, it is likely that YAP1 requires 14-3-3σ to contribute to gemcitabine resistance.  
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Figure 24. YAP1 is over-expressed in resistant G3K cells. (A) Western blot analysis of 
YAP1, p-YAP1 and 14-3-3σ expression in both MiaPaca-2 and G3K cells. Actin was used 
as a loading control. (B) Real time RT-PCR analysis of YAP1 mRNA level in MiaPaca-2 and 
G3K cells (N=3, **p<0.01). 
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Figure 25. Regulation of YAP1 expression by 14-3-3σ protein level. (A) Effect of 14-3-3σ 
knockdown on YAP1/p-YAP1 expression. G3K cells were transiently transfected with 
scrambled control siRNA (Scr) or siRNAs targeting 14-3-3σ followed by Western blot 
analysis of YAP1, p-YAP1 and 14-3-3σ protein level. Actin was used as a loading control. 
(B) Real time RT-PCR analysis of YAP1 mRNA level in G3K cells stably transfected with 
scrambled control shRNA (scr sh3’) or shRNA targeting 14-3-3σ (14-3-3 sh(11)). GAPDH 
was used as internal control. (N=3, **p<0.01). (C-D). Effect of 14-3-3σ over-expression 
on YAP1 expression. MiaPaca-2 cells were stably transfected with vector control (vec(1)) 
or pcDNA3.1(+)-flag-14-3-3σ plasmid (flag-σ(6)) followed by Western blot analysis of 
YAP1, p-YAP1, and 14-3-3σ protein levels (C) or real time RT-PCR analysis of YAP1 mRNA 
level (D). (N=3, **p<0.01). Actin and GAPDH were used as a loading control for Western 
blot and internal control for PCR analysis, respectively. 
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Figure 26. YAP1 over-expression contributes to gemcitabine resistance, but requires 
the presence of 14-3-3σ. (A-B) Effect of YAP1 knockdown on gemcitabine resistance in 
G3K cells. G3K cells were transiently transfected with scrambled control siRNA (Scr) or 
siRNAs targeting YAP1 followed by Western blot analysis of YAP1 and 14-3-3σ protein 
level (A) or MTT assay for detection of drug resistance(B). (N=4, **p<0.01). Actin was 
used as a loading control for Western blot. (C-D) Effect of YAP1 over-expression on 
gemcitabine resistance in MiaPaca-2 cells. MiaPaca-2 cells were transfected with vector 
control (GFP-C2) or GFP-YAP plasmid followed by Western blot analysis of YAP1 protein 
level (C) or MTT assay for detection of drug resistance (D). (N=4, not significant). Actin 
was used as a loading control for Western blot. (E-F) Effect of YAP1 over-expression on 
gemcitabine resistance in 14-3-3σ-over-expressing MiaPaca-2 cells. 14-3-3σ-over-
expressing MiaPaca-2 cells (MiaPaca-2 flag-σ (6)) were transfected with vector control 
(GFP-C2) or GFP-YAP plasmid followed by Western blot analysis of YAP1 protein level (E) 
or MTT assay for detection of drug resistance (F). (N=3, **p<0.01). Actin was used as a 
loading control for Western blot. 
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Figure 26 (cont). 
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B. Gemcitabine resistance requires both 14-3-3σ and YAP1.  
             To better understand the mechanism of 14-3-3σ and YAP1 in contributing to 
acquired gemcitabine resistance, either 14-3-3σ or YAP1 was up-regulated but down-
regulated the other, followed by MTT assay to determine gemcitabine response. As 
shown in Figure 27A-B, over-expressing 14-3-3σ markedly increased YAP1 protein level 
and gemcitabine resistance in MiaPaca-2 cells. However, knocking down YAP1 in 14-3-
3σ-over-expressing MiaPaca-2 cells diminished the 14-3-3σ-induced gemcitabine 
resistance. Similarly, up-regulation of YAP1 in 14-3-3σ-over-expressing MiaPaca-2 cells 
significantly increased gemcitabine resistance, whereas knocking down 14-3-3σ in these 
cells abolished gemcitabine resistance despite that the ectopic YAP1 expression 
maintains at high level (Figure 27C-D). Together, these findings suggest that both 14-3-
3σ and YAP1 are required for gemcitabine resistance. 
             To better address this observation, I performed the double knockdown 
experiment. Either 14-3-3σ or YAP1, or both proteins were knocked down in G3K (Figure 
28A-B) or Aspc-1 (Figure 28C-D) cells to test the changes in gemcitabine resistance. Not 
surprisingly, knocking down either 14-3-3σ or YAP1 alone dramatically reduces 
gemcitabine resistance in both cell lines, by ~61% and ~69% reduction in G3K cells 
respectively. However, knocking down both 14-3-3σ and YAP1 simultaneously did not 
further reduce drug resistance, by ~72% reduction in G3K cells. Thus, it is possible that 
14-3-3σ and YAP1 cooperates with each other to contribute to gemcitabine resistance, 
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and hence it is likely that the mechanism of 14-3-3σ-mediated gemcitabine resisance is 
the same as YAP1-mediated gemcitabine resistance. 
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Figure 27. Gemcitabine resistance requires both 14-3-3σ and YAP1. (A-B) YAP1 
knockdown counteracts increased gemcitabine resistance caused by 14-3-3σ over-
expression. MiaPaca-2 vec(1) and MiaPaca-2 flag-σ(6) cells were transiently transfected 
with scrambled control siRNA (Scr) or siRNAs targeting YAP1 followed by Western blot 
analysis of YAP1 and 14-3-3σ (A) or MTT assay for detection of drug resistance (B). (N=3, 
**p<0.01, ***p<0.001). Actin was used as a loading control for Western blot. (C-D) 14-3-
3σ knockdown counteracts with increased gemcitabine resistance caused by YAP1 over-
expression. MiaPaca-2 flag-σ(6) cells were transiently co-transfected with (1) GFP-C2 
vector and scrambled control siRNA (GFP-C2/Scr si), or (2) GFP-YAP over-expression 
plamid and scrambled control siRNA ( GFP-YAP/scr si), or (3) or GFP-YAP over-expression 
plamid  and siRNA targeting 14-3-3σ (GFP-YAP/14-3-3σ si),  followed by Western blot 
analysis of YAP1 and 14-3-3σ (C) or MTT assay for detection of drug resistance (D). (N=3, 
**p<0.01, ***p<0.001). Actin was used as a loading control for Western blot. 
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Figure 27 (cont). 
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Figure 28. Decreased expression of both 14-3-3σ and YAP1 by RNA knockdown does   
not further reduce drug resistance. G3K cells (A-B) or Aspc-1 cells (C-D) were transiently 
transfected with either scrambled (Scr) siRNA, 14-3-3σ siRNA, and YAP1 siRNA alone, or 
co-transfected with both 14-3-3σ and YAP1 siRNA simultaneously, followed by Western 
blot analysis of YAP1 and 14-3-3σ (A, C) or MTT assay for detection of drug resistance (B, 
D). (N=3-5, *p<0.05, **p<0.01, ***p<0.001, NS: not significant). Actin was used as a 
loading control for Western blot. 
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C. 14-3-3σ and YAP1 form a complex.  
             The finding of indispensable roles of both 14-3-3σ and YAP1 in gemcitabine 
resistance suggests that 14-3-3σ may form a complex with YAP1. To test this possibility, 
co-immunoprecipitation assay was performed in G3K cells transiently transected with 
GFP-YAP1 and flag-14-3-3σ. As shown in Figure 29A, YAP1 and p-YAP1 proteins could be 
co-immunoprecipitated by 14-3-3σ antibody and flag-14-3-3σ protein could be co-
immunoprecipitated by GFP antibody. Thus, 14-3-3σ may bind with YAP1/p-YAP1 to 
form a complex in G3K cells. 
             Next, co-localization analysis of these two proteins was performed using 
immunofluorescence staining. As shown in Figure 29B, both 14-3-3σ and YAP1 appear to 
localize to the cytoplasm of G3K cells and the overlay image indicates their co-
localization, which supports the possibility that these two proteins reside and form a 
complex in the cytoplasm.  
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Figure 29. 14-3-3σ interacts and binds with YAP1 in vitro. (A) 14-3-3σ co-
immunoprecipitates with YAP1, and vise versa. G3K cells were transiently transfected 
with pEGFP-YAP1 plasmid or co-transfected with both pEGFP-YAP1 and pcDNA3.1-flag-σ 
plasmid, followed by immunoprecipitation with either 14-3-3σ or GFP antibody, and 
Western blot detection the existence of YAP1, p-YAP1 or 14-3-3σ in the complex. (B) 
YAP1 co-localizes with 14-3-3σ in vitro. The localization of both YAP1 and 14-3-3σ in the 
G3K cells was visualized by confocal microscopy. 
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D. Both 14-3-3σ and YAP1 protect against gemcitabine-induced caspase-8 activation 
and apoptosis.  
             To further investigate the mechanism of 14-3-3σ and YAP1-induced gemcitabine 
resistance, I tested their effect on gemcitabine-induced apoptosis. 14-3-3σ was knocked 
down in G3K cells to test its influence on gemcitabine-induced apoptosis. As shown in 
Figure 30A, knocking down 14-3-3σ in G3K cells led to dose-dependent increase in 
gemcitabine-induced Parp-1 cleavage, suggesting its potential protective role in 
apoptosis. To confirm this result, a stable knockdown clone was established by 
transfecting the G3K cells with 14-3-3σ shRNA followed by apoptotic assay. Treatment 
the G3K cells with scrambled shRNA with 40 μM or 80 μM of gemcitabine for 24 hrs 
induced apoptosis by ~1.9 fold and ~4.8 fold increase compared with no treatment 
control respectively, whereas in 14-3-3σ knockdown cells it induced more apoptosis, by 
~4.8 fold and ~9.5 fold increase (Figure 30B). The apoptotic assay showed that 14-3-3σ 
knockdown cells appeared to undergo more apoptosis following gemcitabine treatment, 
confirming the protective role of 14-3-3σ against gemcitabine-induced apoptosis. 
Moreover, gemcitabine-induced Parp-1 cleavage was found to be markedly increased in 
14-3-3σ knockdown cells compared with vector shRNA transfected cells (Figure 31A). 
Similarly, knocking down YAP1 in G3K cells also led to dose-dependent increase in 
gemcitabine-induced Parp-1 cleavage, suggesting that YAP1 over-expression may also 
protect G3K cells from gemcitabine-induced apoptosis (Figure 31B). Together, these 
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experiments strongly suggest that both 14-3-3σ and YAP1 up-regulation contribute to 
gemcitabine resistance by inhibiting Parp-1 cleavage and gemcitabine-induced apoptosis. 
             To further investigate the specific apoptotic pathway that 14-3-3σ and YAP1 
participated in, the Western blot analysis was conducted to detect the caspase-8 and 
caspase-9 activation under gemcitabine treatment in G3K cells. As shown in Figure 31A, 
cleaved and active caspase-8 was found to be dramatically elevated in 14-3-3σ 
knockdown G3K cells compared with control cells upon gemcitabine treatment. Similarly, 
knocking down YAP1 in G3K cells also led to an increased activation of caspase-8 
following gemcitabine treatment (Figure 31B). However, caspase-9 activation was not 
affected (data not shown). Thus, likely 14-3-3σ and YAP1 function in inhibiting 
gemcitabine-induced apoptosis by attenuating caspase-8 activation. 
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Figure 30. Decreased expression of 14-3-3σ by RNA knockdown promotes parp-1 
cleavage and apoptotic cell death. (A) G3K cells were transiently transfected with either 
scrambled (Scr) siRNA or siRNA targeting 14-3-3σ, followed by Western blot analysis of 
cleaved parp-1 and 14-3-3σ. Actin was used as a loading control. (B) 14-3-3σ knocking 
down leads to compromised apoptosis. G3K cells stably transfected with either 
scrambled shRNA (scr sh3’) or 14-3-3σ shRNA (14-3-3σ sh(11)) were treated 
with/without various dose of gemcitabine, followed by apoptotic assay to measure the 
enrichment of nucleosomes released in the cytoplasm. (N=5, *p<0.05, **p<0.001).  
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Figure 31. Decreased expression of either 14-3-3σ or YAP1 by RNA knockdown leads     
to increased parp-1 cleavage and caspase-8 activation. (A) G3K cells stably transfected 
with either scrambled shRNA (scr sh3’) or 14-3-3σ shRNA (14-3-3σ sh(11)) were treated 
with or without various dose of gemcitabine, followed by Western blot analysis of 
cleaved parp-1, cleaved caspase-8 and 14-3-3σ. Actin was used as a loading control. (B) 
G3K cells were transiently transfected with either scrambled (Scr) siRNA or siRNA 
targeting YAP1, followed by Western blot analysis of cleaved parp-1, caspase-8 
activation and YAP1. Actin was used as a loading control. 
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             Finally, in order to further confirm its protective role in gemcitabine-induced 
apoptosis, 14-3-3σ was over-expressed in parental MiaPaca-2 cells followed by Western 
blot detection of caspase-8 activation. As shown in Figure 32A, following treatment with 
various doses of gemcitabine, 14-3-3σ over-expression led to much less Parp-1 cleavage 
and caspase-8 activation, with Parp-1 cleavage and caspase-8 activation saw at 20 nM of 
gemcitabine treatment compared to 10 nM in vector control cells, confirming that 14-3-
3σ up-regulation protects MiaPaca-2 cells from gemcitabine-induced caspase-8 
activation and apoptosis. Furthermore, 14-3-3σ over-expression in MiaPaca-2 cells also 
caused a delay of caspase-8 activation at different time points under 100 nM of 
gemcitabine treatment, with caspase-8 activation at 48 hrs compared to 24 hrs in vector 
control cells (Figure 32B), suggesting that the protective role of 14-3-3σ in gemcitabine-
induced apoptosis and caspase-8 activation is not only dose-dependent, but also time-
dependent.  
             Taken together, 14-3-3σ appears to contribute to gemcitabine resistance by up-
regulating YAP1 protein level and then forming a complex with YAP1 and p-YAP1, then 
both 14-3-3σ and YAP1 in the complex may protect against gemcitabine-induced 
apoptosis via attenuating caspase-8 activation (Figure 33). 
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Figure 32. 14-3-3σ over-expression in MiaPaca-2 cells protects against parp-1 cleavage 
and caspase-8 activation. (A) MiaPaca-2 cells stably transfected with vector control or 
pcDNA3.1-flag-σ plasmid were treated with/without various dose of gemcitabine, 
followed by Western blot detection the expression level of cleaved parp-1, cleaved 
caspase-8, and 14-3-3σ. Actin was used as a loading control. (B) MiaPaca-2 cells stably 
transfected with vector control or pcDNA3.1-flag-σ plasmid were treated with 100nM of 
gemcitabine, followed by Western blot detection the expression level of cleaved 
caspase-8 and 14-3-3σ at different time points. Actin was used as a loading control. 
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Figure 33. Schematic model of 14-3-3σ-mediated gemcitabine. 14-3-3σ up-regulation 
in resistant G3K cells mediated gemcitabine resistance by up-regulating YAP1 
expression, binding with YAP1/p-YAP1 as a complex, and together inhibiting 
gemcitabine-induced caspase-8 activation. 
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Discussion 
             Stepwise selections with anticancer drugs have been used as a standard method 
to create model cell lines for laboratory studies and identify novel mechanisms of 
acquired resistance. G3K cells selected with gemcitabine in this study are clonal and 
cross resistant to Ara-C. Considering the similarity in structure, mechanism of action, 
and metabolism between gemcitabine and Ara-C, it was not surprising to find the cross-
resistance of G3K cells to Ara-C. The observation of increased expression of RRM is also 
as expected as these proteins have previously been shown to be up-regulated and 
contribute to gemcitabine resistance in other gemcitabine-selected cells [181, 182]. 
However, the findings of the up-regulated expression of 14-3-3σ via reversible 
epigenetic regulation during gemcitabine selection and its role in acquired gemcitabine 
resistance are unexpected and novel. 
             14-3-3σ, a homo-dimeric protein that functions as a chaperone, binds to >100 
phospho-serine/phospho-threonine proteins and plays an important role in cell survival 
[183]. Up-regulated expression of 14-3-3σ has been found in PDAC and appears to 
associate with poor prognosis of PDAC by causing resistance to gemcitabine [46, 184]. 
However, it remains to be determined if 14-3-3σ plays an important role in clinically 
acquired gemcitabine resistance in PDAC. The possible role of 14-3-3σ in resistance to 
other anticancer drugs such as Adriamycin and cisplatin has also been reported 
previously [60, 61, 63, 65]. Similar to the finding of this study that 14-3-3σ can be 
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selected and responsible for acquired gemcitabine resistance, it can also be selected 
and responsible for acquired Adriamycin resistance [63]. 
             Although some of the other members of the 14-3-3 protein family such as 14-3-
3ζ and 14-3-3θ/τ have been reported to also contribute to [185, 186] and associate with 
[187] drug resistance, respectively, I did not find up-regulation in expression of 14-3-3ζ 
and 14-3-3θ/τ in the gemcitabine resistant G3K cells. This observation suggests that 14-
3-3ζ and 14-3-3θ/τ may not participate in the acquired gemcitabine resistance in PDAC.  
             This study is the first time to find that 14-3-3σ-mediated gemcitabine resistance 
may be possibly through binding with YAP1 and protecting against gemcitabine-induced 
caspase-8 activation and apoptosis. There are two distinct apoptotic pathways, the 
mitochondria pathway with subsequent activation of caspase-9, or the death receptor 
pathway via activation of caspase-8. In this study, I found that 14-3-3σ exerts its 
protective effect mainly by binding to YAP1 and inhibiting gemcitabine-induced 
apoptosis and caspase-8 activation, suggesting that the apoptotic pathway induced by 
gemcitabine is likely the cell death receptor pathway although it remains unclear how 
14-3-3σ/YAP1 complex protects against caspase-8 activation. This study is consistent 
with previous report that gemcitabine induces caspase-8 and caspase-3 activation in 
H292 cells and enhances cell sensitivity to Fas-mediated cytotoxic activity [188], which 
supported our evidence that gemcitabine induces apoptosis by activating caspase-8. 
Moreover, it is also reported that gemcitabine induces apoptosis in non-small cell lung 
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cancer (NSCLC) cells by increasing functionally active Fas (CD95, APO-1) expression, as 
well as up-regulation of Fas ligand (FasL) which triggers cell apoptosis via an 
autocrine/paracrine loop [188, 189], demonstrating the important role of death 
receptor pathway (extrinsic pathway) in contributing  to gemcitabine-induced apoptosis. 
Therefore, it will be interesting to investigate whether or not 14-3-3σ and YAP1-
mediated inhibition of gemcitabine-induced caspase-8 activation by down-regulating or 
inactivating Fas or FasL. Fas stimulation triggers apoptosis via the so-called type I 
extrinsic signaling pathway. Central to this pathway is the direct caspase-8-mediated 
cleavage and activation of caspase-3 as compared to the type II pathway which first 
requires caspase-8-mediated Bid cleavage to trigger mitochondrial cytochrome c release 
for caspase-3 activation. However, in this study, caspase-9 activation under gemcitabine 
treatment seems not be interfered by 14-3-3σ and YAP1 expression, suggesting type I 
extrinsic signaling pathway as the main pathway. In contrast to the well established role 
of caspase-3 as an effector caspase, caspase-3 is also delineated to 
induce feedback activation of the apical caspases including caspase-2, caspase-8, 
caspase-9 and caspase-10A in doxorubicin and TNFα-induced apoptosis [190]. Moreover, 
the positive feedback loop between active caspases-3 and caspase-8 is also reported in 
lymphocytes, hepatocytes and Hela cells [191]. It has shown that fully processed, active 
p17 caspase-3 feeds back on caspase-8 by cleaving its partially processed p43 form into 
the fully processed p18 species [191], suggesting a possibility that 14-3-3σ protects 
against gemcitabine-induced caspase-8 activation by suppressing caspase-3 activation 
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first. Therefore, it will be intriguing to investigate if 14-3-3σ-mediated inhibition of 
gemcitabine-induced caspase-8 activation is dependent on caspase-3 activation or not. 
             Although it is unknown if other mechanisms of 14-3-3σ-induced gemcitabine 
resistance exist, the fact that it binds to various proteins important for different cellular 
processes suggest that other protein partners may also mediate 14-3-3σ-induced 
gemcitabine resistance. Somatic knockout of 14-3-3σ in colon cancer cells has been 
shown to cause drug-induced mitotic catastrophe by reducing cellular ability to arrest in 
G2/M phase [55]. In addition, increased 14-3-3σ expression in breast cancer cells was 
found to make cancer cells more resistant to drug-induced apoptosis [63], possibly due 
to 14-3-3σ binding and arresting cyclin B1 and CDC2 [55, 65] and pro-apoptotic proteins 
such as Bax and Bad [192, 193] in cytoplasm. 14-3-3σ over-expression was also found to 
contribute to cisplatin resistance in gastric cancer cells through Erk and p38 activation 
[194], suggesting a possible role of Erk and p38 in mediating 14-3-3σ-induced 
gemcitabine resistance. Nevertheless, it remains to be determined if 14-3-3σ-induced 
gemcitabine resistance is also via cytoplasmic retention of cyclin B1 and CDC2, 
interference of Erk and p38 signaling pathway, and blockade of mitotic catastrophe. In 
addition, based on similar expression profile of RRM1, RRM2, and 14-3-3σ, and the 
regulatory role of 14-3-3σ on YAP1 expression, it is intriguing to determine whether or 
not 14-3-3σ potentially regulates the expression of RRM1 and RRM2. The possible role 
of 14-3-3σ in regulating gemcitabine metabolism pathway is not studied and remains to 
be investigated. I am currently working toward this direction.            
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             The regulation of 14-3-3σ expression occurs in multiple steps and epigenetic 
regulation by methylation has been observed in cell line models and clinical samples 
although the mechanism of regulation by methylation was unknown [195, 196]. 
However, the increased 14-3-3σ expression following drug selection in different cell 
lines appears to be regulated by different mechanisms. Epigenetic regulation likely 
occurs only in the parental cells where the 14-3-3σ gene is epigenetically silenced in 
MiaPaca-2 cells due to hypermethylation of the promoter. Up-regulation of 14-3-3σ 
expression in Adriamycin-selected and resistant MCF7 cells is likely mediated by other 
mechanisms.  In response to DNA damage, 14-3-3σ is induced in a p53-dependent 
manner, and in turn it positively regulates p53 and suppresses tumor cell growth, 
indicating a positive feedback between 14-3-3σ and p53 [197]. Similar to our finding 
that 14-3-3σ over-expression in Adriamycin-selected and resistant MCF7 cells is not 
mediated by epigenetic regulation, 14-3-3σ mRNA level change in 5-fluorouracil (5-FU)-
selected and resistant MCF7 cells was due to p53 protein expression but not 
methylation level change [198]. Like p53, 14-3-3σ was also found to be transactivated by 
p73 and, in turn, stabilize p73 and enhance the p73-mediated transcriptional activity as 
well as its pro-apoptotic function [199]. Our preliminary study has found that p73 
expression was increased in G3K cells, whereas in parental MiaPaca-2 cells p53 gene is 
mutated, thus it is likely that in G3K cells 14-3-3σ is transactivated by p73. Furthermore, 
except for being regulated by gene methylation and transcription, 14-3-3σ protein was 
also found to be regulated by phosphorylation and proteolytic inactivation [200, 201]. It 
was found that TGFβ1 induced phosphorylation of 14-3-3σ at Ser69 and Ser74, which 
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regulates MCF7 tumor progenitor population and acts as a feed-forward mechanism in 
TGFβ/Smad3-dependent transcription [201]. In addition, the estrogen-responsive E3 
ubiquitin ligase Efp was identified to specifically targets 14-3-3σ for degradation in 
breast cancers [200]. Therefore, both epigenetic silencing by gene methylation, p53 
inactivation, and proteasome-dependent proteolysis leads to loss of 14-3-3σ. 
             In this study, it is the first time to discover that Uhrf1 and DNMT1 bind to 
methylated region and regulate and maintain the hypermethylation status of 14-3-3σ 
gene. The finding that the 14-3-3σ gene could be reversibly methylated by DNMT1 and 
Uhrf1 during gemcitabine selection is consistent with the observation of reduced Uhrf1 
expression in G3K cells, which recruits DNMT1. The finding that 14-3-3σ expression is 
progressively up-regulated during gemcitabine selection suggests that the gene 
demethylation may also be progressive. Although the decreased methylation of the 14-
3-3σ gene in the drug resistant G3K cells is inconsistent with the increased expression of 
DNMT1, but it is consistent with the reduced level of Uhrf1. 
             Uhrf1, a multi-domain protein associated with cellular proliferation and 
epigenetic regulation, binds to histones and methyl-CpG dinucleotides with a preference 
for hemi-methylated CpG sites. The consequence of Uhrf1 binding was recruitment of 
DNMT1 and histone deacetylase 1, resulting in methylation of nascent DNA strands [124, 
126-128]. Thus, reduced Uhrf1 expression in G3K cells is likely responsible for reduced 
methylation of 14-3-3σ gene by reducing recruitment of DNMT1 to the methylated CpG 
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islands despite the presence of high level of DNMT1. In MiaPaca-2 cells, however, the 
high level of Uhrf1 may efficiently recruit enough DNMT1 despite low DNMT1 level for 
sufficient methylation of 14-3-3σ gene. Therefore, knocking down either Uhrf1 or 
DNMT1 in MiaPaca-2 cells would effectively reduce the level of the recruiter (Uhrf1) or 
the pool of DNMT1 to be recruited for methylation of 14-3-3σ gene and consequently 
increase 14-3-3σ expression. Furthermore, the slight increase of Uhrf1 expression in the 
G3KRev cells may be responsible for the increased methylation and reduced expression 
of 14-3-3σ gene. These findings also suggest that other genes that are under epigenetic 
regulation, specifically DNA methylation, may also change in their expression similar as 
14-3-3σ. In addition, I found that p21, a known Uhrf1 downstream target gene, has a 
similar expression profile as 14-3-3σ in the parental MiaPaca-2, gemcitabine resistant 
G3K and revertant G3KRev cells. What other genes have similar expression profile in 
these cells and whether these genes such as p21 also contribute to the acquired 
gemcitabine resistance are very intriguing, and have been partly answered by RRBS 
analysis of global gene methylations.  
             There are several methods available for global DNA methylation evaluation. 
Comparing with MeDIP, MethylCap, the bisulfite-based method RRBS is slightly more 
accurate than the other two enrichment-based methods in identifying Differential 
Methylated Regions (DMRs) [202]. Due to single nucleotide resolution, RRBS has the 
advantage of offering a direct measure of methylation levels without requiring statistical 
correction of CpG bias as in MeDIP and MethylCap. However, the method design of 
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RRBS only focuses on CpG-rich regions (promoters and CG islands) and thus has a much 
lower genomic coverage (RRBS reads are clustered in approximately 1% of the genome) 
than MeDIP and MethylCap, the latter two methods are theoretically capable of 
covering all methylation regions across the whole genome. Despite the great difference 
in genomic coverage, the identified DMRs are similar among these three methods due 
to depth requirement for reliably detecting DMRs that are statistically significant.  
             14-3-3σ gene, which was confirmed to be differentially methylated, nevertheless 
was not listed among the total 65 candidate genes. The reason is that the RRBS read 
coverage for 14-3-3σ gene is only 11.71% and among 27 CpG dinucleotides analyzed 
using traditional bisulfite sequencing, only 4 were covered in the RRBS sequencing 
regions. It is, however, noteworthy that RRBS revealed significant difference in 
differential methylation of 14-3-3σ gene between MiaPaca-2 and G3K cells with a P-
value of 9.23e-15. Moreover, studies on 14-3-3σ gene methylation are focused on its 
first exon, and whether or not 14-3-3σ gene is methylated at its promoter or other 
regions is unknown. Based on our RRBS study that significantly differential methylation 
of 14-3-3σ gene appears only in the region of first exon, CpG islands of 14-3-3σ gene at 
promoter and other regions may not be frequently methylated. 
             It is widely recognized that gene methylation at the promoter may affect gene 
transcription and expression. However, among the 10 candidate genes selected by 
DMRs from RRBS analysis, two had no change in mRNA levels as determined using real 
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time RT-PCR. Thus gene methylation change in the promoter region may not necessarily 
lead to mRNA level change. In general, gene silencing has been thought to be either due 
to direct inhibition of transcription factor binding by DNA methylation or mediated by 
methyl-binding domain (MBD) proteins that recruit chromatin-modifying complexes to 
methylated DNA  to bring about further changes in chromatin structure: prototypically 
those associated with nucleosomal compaction and transcriptional silencing [203, 204]. 
The linkage between gene promoter methylation and heritable transcriptional 
suppression is well recognized, however, it seems that CG Island (CGI) methylation is not 
the initiating event in gene silencing, but acts to lock in the silent state. For example, 
during X-chromosome inactivation, X-linked CGIs do not become methylated until after 
gene silencing and the acquisition of several silencing chromatin modifications, such as 
H3K27me3 [205, 206]. Moreover, the majority of CGIs that gain methylation during 
differentiation are already silent in embryonic stem cells, providing further evidence 
that gene silencing precedes DNA methylation [207]. Therefore, the causative 
relationship between gemcitabine selection and differential gene methylation is unclear. 
In addition, using regionally methylated plasmids, it has been reported that parameters 
such as position, length, or density of methylated cytosines are crucial for the efficiency 
of gene repression [208-210]. Furthermore, other studies also suggested that 
transcriptional inhibition relies on methylation at specifically critical CpG sites [211-213]. 
Thus, it is likely that DMRs of some genes in our RRBS analysis are not the key CpG sites 
and hence the gene transcription is not affected. Noticeably, it was also reported that 
densely methylated elements (DMEs) of the genome are disproportionately enriched for 
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exons, and that DNA methylation in the region of the first exon is much more tightly 
linked to transcriptional silencing than methylation in the upstream promoter region 
[214], indicating a more predictive role of first exon rather than promoter region in gene 
silencing. Moreover, it was demonstrated that methylation of promoter sequences does 
not have a greater repressive effect than the modification of flanking, nonregulatory 
DNA sequences, and that the presence of a transcription factor can compete for the 
establishment of an inactive promoter conformation, thus reducing the silencing effect 
[215]. Additionally, the existence of factors indifferent to DNA methylation status and 
the demonstration that this modification is often capable of repressing transcription 
only after chromatin has been assembled suggest that other factors such as chromatin 
structure may impede DNA methylation-mediated gene silencing [210, 216, 217]. 
Thereby, gene transcription and repression is a complicated process and the 
methylation of CpG islands located in gene promoters is not always equated with 
transcriptional inactivity, other factors such as methylation density, critical CpG 
methylation sites, competing transcription factors as well as chromatin status and other 
player participating in gene transcription and repression complex should also be 
considered.  
             PDGFD, as the latest addition to PDGF family, has generated considerable 
interest in recent years because of its up-regulation and involvement in the progression 
of many types of human cancers [147-153]. The growing body of literature strongly 
suggests that PDGFD may function as a key player in the development and progression 
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of human cancers by regulating the processes of cell proliferation, apoptosis, migration, 
invasion, angiogenesis, and metastasis. It has been reported that PDGFD signaling is 
frequently deregulated in human malignancies and PDGFD expression was up-regulated 
in many human cancers including prostate, lung, renal, ovarian, brain, and pancreatic 
cancer [146, 147, 149-152]. Pancreatic cancer, like many other tumors, has been shown 
to over-express PDGFD. However, the association of PDGFD with drug resistance, 
especially gemcitabine resistance in pancreatic cancers, is unknown. This study not only 
identified PDGFD as an important contributor of gemcitabine resistance for the first 
time, but also newly investigated its methylation status in the promoter region. Thus it 
is very possible that the up-regulated expression of PDGFD found in many other cancers 
was also accredited to gene demethylation, and if so, targeting PDGFD gene methylation 
and over-expression may be a useful therapeutic approach to overcome different 
human tumors.  
             It is known that PDGFD upregulation triggers a number of downstream signaling 
pathways including activation of phosphatidylinositol 3 kinase (PI3K), Akt, nuclear 
factor-κB (NF-κB), Notch, and extracellular signal-regulated kinase (ERK) [139, 145-147]. 
Here, it is the first time to show a direct association of PDGFD expression and activation 
of Stat3 signaling pathway. However, other signaling pathways that might regulate 
PDGFD-mediated gemcitabine resistance are not excluded. Thus it is interesting to 
investigate other downstream signaling pathways of PDGFD such as NF-κB and ERK to 
complete the study of molecular mechanisms of PDGFD-induced gemcitabine resistance. 
123 
 
It is noteworthy that in addition to PDGFD, the methylations of PDGFB and PDGFC genes 
were also found significantly reduced in G3K cells compared with MiaPaca-2 cells, based 
on the RRBS analysis. Therefore, it will be of interest to determine if the methylation 
change of both PDGFB and PDGFC genes also leads to increased gene transcription and 
protein expression, and whether these two genes also play important roles in acquired 
gemcitabine resistance. 
             The overall outcome of this study suggests the importance of epigenetic 
alterations, specifically methylation of chromatin DNA, which may play an important 
role in gemcitabine resistance. It also revealed a critical role of 14-3-3σ and PDGFD in 
acquired gemcitabine resistance. Finally, targeting 14-3-3σ, PDGFD, and perhaps DNA 
methylation may be considered for therapeutic development in combinational 
treatment to overcome gemcitabine resistance.  
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Summary and Conclusion 
             The experimental results of this dissertation can be summarized as follows: 
             1. Acquired gemcitabine resistant cell line G3K is cross-resistant to Ara-C, but not 
to other anticancer therapeutic drugs been tested. 
             2. In addition to increased RRM1/2, 14-3-3σ expression and transcription level 
are dramatic elevated in gemcitabine-resistant cells. 
             3. Down-regulation of 14-3-3σ expression in gemcitabine-resistant cell line G3K 
decreases drug resistance level to both gemcitabine and Ara-C. 
             4. Ectopic over-expression of 14-3-3σ in the parental MiaPaca-2 cells increases 
resistance to both gemcitabine and Ara-C. 
             5. 14-3-3σ gene in the parental MiaPaca-2 cells is hyper-methylated, whereas in 
gemcitabine-resistant G3K cells it is hypo-methylated. 
             6. Demethylation of 14-3-3σ gene during gemcitabine selection is partially 
reversible followed by drug retrieval. 
             7. Although 14-3-3σ expression is up-regulated in Adriamycin-resistant breast 
cancer cell line MCF7/Advp3000, the methylation status of 14-3-3σ gene remains 
unchanged during Adriamycin selection. 
             8. The expression level of DNMT1 in gemcitabine-resistant G3K cells is markedly 
increased, while down-regulation of DNMT1 in parental MiaPaca-2 cells restores 14-3-
3σ gene expression. 
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             9. The expression level of Uhrf1 in gemcitabine-resistant G3K cells is dramatically 
decreased, and down-regulation of Uhrf1 in parental MiaPaca-2 cells leads to 14-3-3σ 
gene re-expression. 
             10. Both Uhrf1 and DNMT1 bind to methylated region of 14-3-3σ gene in the 
parental MiaPaca-2 cells, together function to repress 14-3-3σ gene expression. 
             11. DNMT1 protein is recruited by Uhrf1 for binding to 14-3-3σ gene, and down-
regulation of Uhrf1 in MiaPaca-2 cells affect DNMT1 binding. 
             12. Through RRBS, 845 genes are found differentially methylated comparing 
MiaPaca-2 and G3K cells, and 282 genes found differentially methylated comparing G3K 
and G3KRev cells. 
             13. PDGFD gene is reversibly demethylated during gemcitabine selection, and 
the reversible demethylation leads to corresponding increase/decrease of gene 
transcription and protein expression. 
             14. Down-regulation of PDGFD in gemcitabine resistant G3K cells and Aspc-1 cells 
compromises gemcitabine resistance. 
             15. Ectopic over-expression of PDGFD in parental MiaPaca-2 cells escalates cell 
resistance to gemcitabine. 
             16. The expression level of STAT3, p-stat3, and STAT3 downstream targets MMP2 
and VEGF is increased in gemcitabine resistant G3K cells compared with MiaPaca-2 cells. 
             17. Down-regulation of PDGFD in gemcitabine resistant G3K cells impairs STAT3 
signaling pathway, whereas ectopic over-expression of PDGFD in parental MiaPaca-2 
cells activates STAT3 signaling pathway. 
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             18. Ectopic over-expression of STAT3 in parental MiaPaca-2 cells increases drug 
resistance to gemcitabine. 
             19. The expression level of YAP1/p-YAP1 is increased in gemcitabine-resistant 
G3K cells. 
             20. Both the protein and mRNA levels of YAP1 are regulated by 14-3-3σ 
expression. 
             21. Down-regulation of YAP1 in gemcitabine-resistant G3K cells leads to 
sensitization to gemcitabine treatment. 
             22. Ectopic over-expression of YAP1 in MiaPaca-2 cells dramatically increases 
gemcitabine resistance, whereas it requires existence of 14-3-3σ. 
             23. Down-regulation of 14-3-3σ or YAP1 reduces gemcitabine resistance caused 
by the up-regulation of YAP1 or 14-3-3σ. 
             24. Down-regulation of either 14-3-3σ or YAP1 in gemcitabine resistant G3K cells 
and Aspc-1 cells reduces gemcitabine resistance, while down-regulation of both proteins 
do not further reduce drug resistance. 
             25. 14-3-3σ and YAP1/p-YAP1 binds to each other in gemcitabine resistant G3K 
cells, and co-localizes at the cytoplasm. 
             26. Down-regulation of either 14-3-3σ or YAP1 in gemcitabine resistant G3K cells 
leads to increased PARP-1 cleavage and caspase-8 activation under gemcitabine 
treatment. 
             27. Over-expression of 14-3-3σ inhibits and delays parental MiaPaca-2 cells from 
gemcitabine-induced PARP-1 cleavage and caspase-8 activation. 
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Future Plans 
             The key findings of my current study showed: 1) the contribution of 14-3-3σ 
over-expression in acquired gemcitabine resistance and its reversibly epigenetic 
regulation by Uhrf1 and DNMT1 during gemcitabine selection; 2) identification of 
PDGFD as a differentially methylated gene during gemcitabine selection and as a critical 
contributor to gemcitabine resistance; 3) 14-3-3σ mediated gemcitabine resistance at 
least partially by binding with YAP1 protein and together protecting against caspase-8 
activation and apoptosis induced by gemcitabine. Future directions that may extend the 
current are: 
             1. Based on similar expression and methylation profile of 14-3-3σ and PDGFD, it 
is possible that PDGFD gene is epigenetically regulated by the same machinery as 14-3-
3σ. Therefore, it is very interesting to investigate whether or not Uhrf1 and DNMT1 also 
binds to the methylated region of PDGFD gene and function to repress its expression. 
Another gene of interest is p21 the protein expression profile of which is found to be 
same as 14-3-3σ, yet other studies has demonstrated that Uhrf1 binds to p21 promoter 
to repress its gene expression. Thereby, it will be interesting to investigate the 
methylation status of p21 gene during gemcitabine selection and whether or not the 
increased expression of p21 contributes to acquired gemcitabine resistance. In addition, 
other proteins such as HDAC1 and methyl-CpG binding proteins like MeCP2 should also 
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be tested to better understand dynamic changes of "Epigenetic Code Replication 
Machinery" of 14-3-3σ and PDGFD gene during gemcitabine selection. 
             2. RRBS data shows a global methylation profile change during gemcitabine 
selection, yet our top candidate gene PDGFD was only screened among 10 genes 
transcriptionally tested. Therefore, it is highly possible that there are other genes with 
methylation status change also play important roles in acquired gemcitabine resistance. 
Hence continuous discovery of other genes participating in gemcitabine resistance is 
critical and helps to better understand the complex process of gemcitabine resistance, 
as well as helps improvement of clinically therapeutic treatment for pancreatic cancer 
patients in the future. 
             3. 14-3-3σ and YAP1 over-expression are shown to inhibit gemcitabine-induced 
caspase-8 activation, which belongs to death receptor pathway. Therefore, whether or 
not 14-3-3σ and YAP1 mediate through extracellular signals and what is the detail 
mechanism of inhibiting caspase-8 activation are intriguing and need to be further 
investigated. Moreover, solid evidence is lacked to prove the importance of caspase-8 
inhibition in 14-3-3σ-mediated gemcitabine resistance, and thus the usage of caspase-8 
inhibitor or siRNA would help demonstrate this hypothesis. Furthermore, since caspase-
3 feeds back on caspase-8 for its activation, it is very interesting to dissect the process of 
which 14-3-3σ and YAP1 inhibit caspase-8 activation and whether or not inhibition of 
caspase-3 activation precedes inhibition of capsase-8 activation. Therefore, utilizing a 
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caspase-3 inhibitor or siRNA would be necessary to help understand the process. If 
inhibition of caspase-3 precedes inhibition of caspase-8 activation, then future research 
should focus on the molecular mechanism by which 14-3-3σ and YAP1 inhibit 
gemcitabine-induced caspase-3 activation. 
             4. This study showed that 14-3-3σ up-regulation contributes to acquired 
gemcitabine resistance by up-regulating YAP1 and together inhibit gemcitabine-induced 
apoptosis. However, since 14-3-3σ is a chaperon protein and binds >100 protein ligands, 
YAP1 binding followed by inhibition of gemcitabine-induced apoptosis may not the sole 
mechanism by which 14-3-3σ contributes to gemcitabine resistance. Thereby, other 
possibilities including but not limited to cytoplasmic retention of CDC2-Cyclin B1 
complexes, prevention of mitotic catastrophe, and interference of gemcitabine 
metabolic pathway should also be investigated. In addition, this study also showed that 
PDGFD over-expression contributes to acquired gemcitabine resistance possibly by 
activating Stat3 signaling pathway, yet other signaling pathways downstream of PDGFD 
activation are not investigated. Therefore, future studies should also focus on other 
possible signaling pathways like NF-κB and ERK pathway that might mediate PDGFD-
induced acquired gemcitabine resistance. 
             5. This study suggests a bystander effect of resistant cells on sensitive cells as 
shown in Figure 20D, indicating that co-culturing MiaPaca-2 cells with G3K cells likely 
makes MiaPaca-2 cells more resistant to gemcitabine treatment compared to MiaPaca-2 
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cells being surrounded by its own. Hence, it will be very interesting to test this 
hypothesis. In order to do so, stable clones of MiaPaca-2 cells with GFP vector plasmid 
(MiaPaca-2-GFP cells) should first be established, followed by performing a colony 
formation assay comparing colonies with green fluorescence under gemcitabine 
treatment in both experimental group of MiaPaca-2-GFP cells co-cultured with G3K cells 
and control group of MiaPaca-2-GFP cells co-cultured with MiaPaca-2 cells. The long-
term goal of this direction is to inject MiaPaca-2-GFP cells with either G3K cells or 
MiaPaca-2 cells into mice xenograft model to compare the growth of MiaPaca-2-GFP 
cells in each group and their responses to gemcitabine treatment. 
             6. Overall, this research identified 14-3-3σ and PDGFD overexpression by 
epigenetic regulation and their contribution to acquired gemcitabine resistance, and 
long-term goals should move forward toward this direction. I have previously 
established stable clones of 14-3-3σ over-expression and PDGFD over-expression in 
MiaPaca-2 cells, and stable knockdown clones of 14-3-3σ in G3K cells, and thus stable 
knockdown clones of PDGFD should also be generated. Then these four pairs of stably 
over-expression or knockdown cells will be injected into nude mice xenograft, followed 
by gemcitabine treatment and comparison of parameters including tumor size, tumor 
volume, mouse survival and death, response to gemcitabine treatment, tumor growth 
and apoptosis, and tumor angiogenesis and metastasis. These in vivo experiments will 
help verify the critical role of 14-3-3σ and PDGFD in gemcitabine resistance. Because 
both 14-3-3σ and PDGFD were identified to be up-regulated in tissue specimens of 
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pancreatic cancer patients [46, 147], if these in vivo experiments show any significance 
of survival benefit, it will be very intriguing and important to test this effect in 
pancreatic cancer patients. First of all, inhibitors of both 14-3-3σ and PDGFD need to be 
developed. Then pancreatic cancer patients, especially those with advanced and 
resistant pancreatic cancers, will receive combinational therapies of gemcitabine with 
14-3-3σ inhibitor or gemcitabine with PDGFD inhibitor within a safe dose range. This 
study may finally lead to a discovery and improvement of a successful treatment 
regimen for pancreatic cancer patients. 
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Appendices 
Appendix 1. List of 230 genes the methylations of which are increased in G3K cells 
compared to MiaPaca-2 cells: 
ABHD14A, ABHD14A-ACY1, ACSS1, ADAM23, ADCY3, ADM, ADORA2A, ADORA2B, 
ADRA2B, AGXT2L1, AKNA, ANGPTL6, ANKRD20A2, AP3B1, ARHGAP22, ARHGDIA, 
ARHGEF6, ARHGEF7, ART5, ASAH2B, ATG5, B4GALT6, BCKDK, BCL11B, BDH1, BMP6, 
BMPR1B, BTBD11, C16orf59, C17orf96, C17orf97, C1orf229, C22orf34, C4orf48, C7orf25, 
CABP1, CACNG2, CAMK2D, CD8A, CDC42EP1, CDC42EP3, CDH15, CDH4, CDK5R1, 
CDKN2AIP, CERKL, CHID1, CHRND, CHSY1, COBLL1, CPLX2, CPNE7, CRHR1, CTAGE1, 
CYP1B1, DAB2IP, DACH1, DACT2, DFNB59, DUSP4, EBF3, ECHDC2, EFNA3, EPHA4, EPHA8, 
ERVK13-1, ESRP2, FAM167A, FAM176C, FAM219A, FASN, FBXO27, FBXO44, FGFRL1, 
FLJ45983, FLJ46257, FOS, FOXF2, FYCO1, GADD45B, GALNTL4, GBX2, GJB2, GLIS3, GPC2, 
GPR160, GPSM1, HBQ1, HCN2, HMHA1, HRASLS, HTT-AS1, IAH1, IGF2-AS, IQSEC2, ITPKA, 
JAG2, JDP2, KBTBD11, KCNQ2, KCNQ4, KCNS2, KCTD15, KDELC1, KIF1A, KLF11, KLF8, 
KLHDC7B, KREMEN2, LARGE, LCP1, LEMD3, LINC00159, LINC00293, LINC00461, 
LINC00473, LLGL2, LMF1, LOC100128946, LOC100131825, LOC285577, LOC286083, 
LOC643923, LOC728613, LOC728716, LRRC32, LRRFIP1, LYNX1, MAFK, MAP2K3, 
MAPRE2, MAST3, MDFI, MESDC1, MGMT, MIR1915, MIR3201, MIR3621, MIR4724, 
MIR598, MMP17, MORN3, MRPS6, MST1P2, MYH11, MYO1B, NCR3LG1, NFATC1, NFIB, 
NGEF, NINL, NOD2, NPAS2, NRIP3, OLIG1, OR1F1, OSMR, OVOL2, PALLD, PARD3B, 
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PCGF5, PCSK6, PDLIM1, PEX6, PODXL2, POU3F1, PPM1E, PPOX, PRAF2, PRELID1, PTGFRN, 
PTK6, PTMA, PTPN21, PTPRG, PWWP2B, RASSF2, RHBDD1, RHOB, RIMBP2, RNF144B, 
RPS6KL1, RRAGC, RSPO1, SALL1, SAMD4A, SIM2, SLC16A14, SLC3A2, SLC45A1, SLC7A5P2, 
SLCO5A1, SMARCA2, SNORD56B, SNORD68, SNTG2, SOWAHC, SOX13, ST6GAL1, STK3, 
SUPT7L, SYCE3, TBR1, TFCP2L1, TMEM17, TMEM179, TMEM181, TMEM200B, TNFRSF6B, 
TNRC18, TPO, TRABD2B, TSC22D4, USH1G, VEGFC, VPS37D, VWCE, WNT3, WNT9A, 
XIRP1, ZBTB47, ZDHHC2, ZNF213, ZNF232, ZNF396, ZNF442, ZNF512, ZNF717, ZNF763, 
ZYX 
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Appendix 2. List of 615 genes the methylations of which are decreased in G3K cells 
compared to MiaPaca-2 cells: 
AATK-AS1, ABCG1, ABHD8, ABLIM2, ABR, ABRACL, ACTB, ADAM19, ADAMTS3, 
ADAMTSL4, ADM, ADRA2A, ADRB1, ADRB2, ADSSL1, AFAP1L2, AFF3, AGFG2, AGPAT3, 
AKR1B1, ALKBH7, ALS2CR8, AMIGO1, AMOTL1, ANK1, ANKRD18DP, ANKRD6, ANXA2P3, 
APBA1, APBB2, AQP7P1, ARAP3, ARC, ARHGAP5, ARNTL, ARNTL2, ASTE1, ATP8B2, 
ATRNL1, BAD, BANK1, BARX2, BATF3, BBX, BCL7A, BCOR, BCR, BDH1, BIK, BIN1, BLM, 
BMP6, BRSK2, C10orf10, C10orf129, C11orf70, C14orf132, C14orf180, C15orf59, 
C18orf25, C1orf204, C22orf34, C2orf82, C5orf55, C6orf141, C9orf106, C9orf96, CABLES2, 
CACNA1D, CACNA1I, CACNG4, CAMK2B, CAMK2G, CAV2, CBR3-AS1, CBS, CBX8, 
CCDC109B, CCDC149, CCDC174, CCDC71L, CCNO, CDC42BPB, CDK6, CDYL, CEBPA, 
CELSR1, CERS4, CHAC1, CHD7, CHRM4, CHRNA7, CHST1, CHST15, CIB2, CIDEA, CKAP4, 
CLDN11, CLDN4, CLK3, CLPTM1L, CMTM3, COL11A2, CPE, CPEB2, CPNE5, CRADD, 
CRAMP1L, CREG2, CT62, CTAG1A, CTAG1B, CTIF, CTSO, CXCL1, CXXC5, CYP2W1, DACT2, 
DBNDD1, DBP, DCAF5, DCTD, DDIT4L, DENND3, DGAT1, DGKZ, DIXDC1, DLL1, DLX4, 
DNAJB1, DNAJB2, DNMT3B, DOC2A, DPF1, DPYSL5, DRD3, DSE, DUS3L, DUSP15, DUSP6, 
EBF3, ECE1, EFNA5, EGLN3, EHBP1L1, ELANE, ELFN1, ELOVL2-AS1, ELOVL7, ENO3, ENOX1, 
EPS8, ERF, ERICH1, ESYT2, ETHE1, ETS2, ETV2, EXD3, EXPH5, F3, FAM102A, FAM105A, 
FAM133B, FAM155A, FAM160B1, FAM196A, FAM198B, FAM211A, FAM213A, FAT4, 
FBXL16, FBXO6, FGF18, FGF19, FGF8, FHOD1, FLJ30403, FLJ42102, FMNL1, FMNL3, 
FOXF1, FRAS1, FTMT, FUCA1, FUOM, GAB1, GADD45B, GADD45G, GALNT7, GALNTL4, 
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GAS1, GGN, GLCCI1, GMNC, GNG7, GNS, GORASP1, GPR123, GPR132, GPR146, GPS1, 
GPX4, GRHL1, GRIA2, GRM4, GSN, GSTO2, H2AFY2, H3F3AP4, HDAC5, HERPUD2, HEY1, 
HIPK3, HIVEP2, HLA-B, HLA-C, HLA-L, HLX, HMP19, HNRNPD, HOXA3, HOXB2, HOXB9, 
HS3ST3B1, HSD11B2, HTR6, HUNK, IDH2, IFITM3, IGF2BP2, IGSF3, IKBKE, IL15RA, IL17RA, 
IL20RB, INPP4B, INS, INSIG1, INSIG2, INTU, IRF2BPL, IRF5, IRS1, ITGA9, JARID2, JMJD8, 
KANK3, KANK4, KC6, KCNC1, KCNH3, KCNJ12, KCNK18, KCNK9, KIAA1024, KIAA1199, 
KIAA1324L, KIF1A, KIF21B, KIF6, KIT, KLF13, KLHL36, KLHL4, KLK6, KNDC1, KRBA1, 
KRT19P2, KSR2, L3MBTL2, LACC1, LEF1-AS1, LGI3, LHB, LIMCH1, LINC00112, LINC00290, 
LINC00347, LINC00461, LINC00667, LITAF, LMO1, LOC100128511, LOC100271722, 
LOC100288974, LOC100506190, LOC158572, LOC255512, LOC283663, LOC283922, 
LOC284751, LOC389895, LOC643355, LOC645752, LOC648987, LOC728875, LONRF3, 
LPAL2, LPHN2, LPPR3, LRIG1, LRRC43, LRRC6, LRRCC1, LRRK1, LSP1P3, LTBP3, LYPD3, 
MAML3, MAMSTR, MAN1A1, MAN1C1, MAPK4, MARK1, MB21D1, MBOAT2, MC4R, 
MCOLN3, MCTP1, MDFIC, MED12L, MEGF9, MEIS2, MERTK, METTL10, MFAP3L, MGAT5B, 
MGC21881, MGC45800, MICALL1, MIDN, MIR101-1, MIR130B, MIR153-1, MIR205HG, 
MIR3182, MIR4456, MIR4479, MIR4634, MIR4787, MIR548I2, MIR573, MIR589, MLL3, 
MLL4, MLLT6, MMP25, MMP28, MN1, MNX1, MSI1, MTA1, MUC6, MYO6, NAAA, 
NAGPA-AS1, NAT8L, NCKAP5L, NDRG4, NDUFV2, NEIL1, NEK11, NINJ2, NIPAL1, NIPAL4, 
NKX1-2, NMU, NOTUM, NQO2, NR4A1, NR4A2, NRARP, NRN1, NSG1, NTNG2, NTSR1, 
NUDT16, OGDHL, OR2L1P, OSBPL7, OSTF1, OTOF, PABPC1L, PABPC5, PALM, PANX2, 
PAOX, PAQR5, PAQR8, PARD6G, PARP11, PARP8, PARP9, PAX2, PCDHGC3, PDGFB, 
PDGFC, PDGFD, PDK3, PDPR, PDZD2, PF4, PGAP2, PGF, PHLDA2, PHLDA3, PIK3IP1, 
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PIK3R1, PITPNM2, PKNOX2, PLEKHA5, PLEKHG1, PLXNA2, PMAIP1, PPCS, PPFIBP2, 
PPM1E, PPM1H, PPM1K, PPP1R14C, PPP4R4, PRDM1, PRDM5, PRDM6, PRKCDBP, PRKCZ, 
PSD2, PSMD1, PTBP1, PTCH2, PTPRK, PXDN, QPCT, RAB12, RAB26, RAB3B, RAET1G, 
RANBP17, RAPGEF4, RASAL2-AS1, RASD2, RASSF9, RCCD1, RHPN1-AS1, RIMBP3B, RIPK4, 
RNASET2, RNF126, RNF152, RNF207, RNLS, RNPEPL1, ROBO2, ROCK2, RPA4, RTN1, RXRA, 
SAPCD2, SARM1, SBNO2, SCAND2, SCD5, SCOC, SCRN1, SDC3, SDK1, SDK2, SEL1L3, 
SEMA4F, SEMA5B, SEPHS2, SEPT11, SEPT4, SEPT5, SEPT8, SEPT9, SERPINE2, SETMAR, 
SFRP1, SH3BGRL2, SHH, SHOX2, SKIDA1, SLC16A7, SLC16A9, SLC22A20, SLC25A27, 
SLC27A1, SLC2A11, SLC31A2, SLC35D3, SLC37A2, SLC44A3, SLC4A8, SLC6A8, SLITRK5, 
SMCR8, SMTNL2, SNORA47, SNORD82, SNX24, SNX33, SOCS1, SOCS3, SOWAHD, SOX4, 
SOX6, SOX7, SPAG1, SPATA31D1, SPATA6, SPATA6L, SPECC1, SPHK1, SQSTM1, ST3GAL1, 
ST3GAL5, STK11, STK32C, STOX1, STOX2, SULF2, SUV420H1, SYNE4, SYT12, SYT7, TACC3, 
TALDO1, TBC1D14, TBC1D9, TBL1XR1, TBX2, TBXAS1, TCF7, TCTE1, TDRD7, TEAD3, 
TENM3, TFAP2A, TFAP4, THBS2, THEMIS2, TIGD2, TMEFF1, TMEM150C, TMEM179B, 
TMEM181, TMEM38A, TMEM56-RWDD3, TMX4, TNFSF9, TNK2, TNNI3, TNS3, TP53TG1, 
TPBG, TPM1, TPM2, TPRA1, TRIL, TRPC3, TSKU, TSPAN14, TSPAN15, TSPAN18, TSPAN5, 
TTC23L, TTC9, TXN2, TXNRD1, UBE2E2, UHRF1, ULK1, UPP1, UST, VAX2, VEGFC, VPS13D, 
VTI1B, WDR1, WIPF3, WNT11, WNT2B, WNT4, WNT8B, WSCD2, WWC2-AS2, ZC3HAV1L, 
ZFAND2A, ZFAND4, ZFHX3, ZFP36, ZFYVE28, ZNF136, ZNF14, ZNF223, ZNF253, ZNF32, 
ZNF362, ZNF385C, ZNF419, ZNF44, ZNF440, ZNF469, ZNF516, ZNF517, ZNF555, ZNF593, 
ZNF669, ZNF700, ZNF771, ZNF808, ZNF83, ZNF833P 
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Appendix 3. List of 140 genes of which the methylations are increased in G3KRev cells 
compared to G3K cells: 
AFAP1L2, ANXA2P3, APBA1, APOBEC3A, B3GNT5, C10orf11, C14orf37, C1orf21, 
C22orf26, CAMK2D, CCNO, CDC42BPB, CDCA7L, CDK6, CHRNA7, CHURC1-FNTB, CNN3, 
CRAMP1L, CTAGE1, CYP11A1, DDIT4L, DDX60, DGCR6, DSE, DUSP6, EFNA5, EGR4, 
ELOVL2-AS1, EPHA7, FAM133B, FAR2, FLJ30838, FRAS1, FRMD6, FUOM, GALNT6, 
GALNT7, GALNTL1, GDPD5, GFPT2, GLIS3, GNS, GPR160, GREB1L, GRM4, GULP1, H2AFY2, 
HIC2, HIVEP2, HLA-A, HLX, HNRNPD, HRASLS, IL15, INSIG1, IRAK1BP1, JMJD8, KCNQ4, 
KIAA1324L, KIAA1609, KIF21A, KIF21B, KLF15, KLHL13, LINC00290, LOC100287042, 
LOC100506190, LOC285577, LOC648987, LONRF3, LRR1, MCTP1, MDFIC, MIR205HG, 
MIR4473, MIR4479, MIR573, MLPH, MMP25, MTA1, NFIA, NKX1-2, NOBOX, PARP4, 
PCDH9, PDGFD, PHF10, PLXNA1, PPM1H, PRDM1, PRKAG2, PRR5L, PTGES, RAB39B, 
RAD21L1, RAET1G, RASD2, RASSF1, RGS2, RNASET2, ROR2, RSPO4, RUNDC3A, SAMD13, 
SAMD5, SEMA5B, SERTAD1, SFXN3, SLC16A7, SLC19A2, SLC25A27, SLC31A2, SLC35D3, 
SLC35G2, SLC7A5P1, SOWAHD, SPATA31D1, STK17A, TMA16, TMEM181, TMEM200B, 
TRABD2A, TRIL, TRPC3, VDR, VENTXP7, VGLL3, WDR1, WNT11, WNT6, ZNF160, ZNF470, 
ZNF593, ZNF611, ZNF630, ZNF669, ZNF704, ZNF789, ZNF808, ZNF83 
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Appendix 4. List of 142 genes of which the methylations are decreased in G3KRev 
cells compared to G3K cells: 
ABCB6, ACAP3, ACOT11, ADAP1, ADORA2B, AHNAK2, AKT3, AMOTL2, ARAF, ARHGAP29, 
ARHGEF6, ARX, ASAP1-IT1, BCL7A, BCOR, C15orf59, C9orf106, CACNG6, CBFA2T3, CBX8, 
CDC42EP3, CELSR1, COL18A1, COL18A1-AS1, CPNE7, CSTB, CUX1, CXXC5, DGKE, DOCK3, 
DPYSL2, EDN2, EIF4E3, ELFN1, EPS8L1, ERVK13-1, EXD3, FAM131B, FAM174A, FAM84B, 
FBXO27, FGFRL1, FOXQ1, GADD45B, GAS1, GBX2, GFOD1, GPM6B, GPSM1, GRIN1, HCN2, 
IKBKE, IMPA2, INS, IRX3, JAG2, KCNH3, KLF4, KLHL29, LHX4, LHX9, LINC00523, 
LINC00674, LMX1B, LOC284751, LOC339874, LOC643355, LRRK1, MAGED4, MAGIX, 
MB21D1, MFI2, MIR124-3, MIR1915, MIR4456, MIR4516, MIR4686, MMEL1, MN1, MPG, 
MRPS6, MUC17, MXRA7, NCOR2, NEDD4L, NFIA, NPAS2, NR2F6, NT5DC2, NUDT11, 
NUP210, NXN, OAZ1, OLIG1, OR1F1, PAX2, PDGFB, PFKFB2, PIP5K1C, PLEC, PNPLA7, 
PPARG, PRDM16, PRR5, PTPRG, PWWP2B, RALGPS2, RBMS1, RIPK4, RNU6ATAC, SATB1, 
SCARNA3, SERPINE2, SESTD1, SH3GL1, SHOX2, SIM2, SLC25A17, SLC25A39, SLC45A1, 
SLC9A3R2, SMAD3, SNCG, SNORD56B, SNORD68, SOCS1, SOX13, SSTR5, TENC1, TET3, 
TJP3, TNRC18, TPRN, TTYH1, TXN2, WNT9A, WSCD2, WWC3, XIRP1, ZNF213, ZNF555, 
ZNF761 
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Appendix 5. List of 309 genes of which the methylations are increased in G3KRev cells 
comparing with MiaPaca2 cells: 
ABHD14A, ABHD14A-ACY1, ACSS1, ADM, ADORA2A, AGXT2L1, AKNA, ANGPTL6, ANKH, 
ANKRD20A2, APOBEC3A, ARHGAP22, ARHGDIA, ARHGEF16, ARHGEF7, ARL6IP4, ARRDC4, 
ARSD, ART5, ASAH2B, ATF3, ATG5, B3GNT5, B4GALT6, BAHCC1, BBX, BCKDK, BCL11B, 
BDH1, BMP6, BMPR1B, BSX, BTBD11, C14orf132, C17orf96, C17orf97, C1orf21, C1orf229, 
C20orf112, C22orf34, C4orf48, C7orf25, CA12, CABP1, CALN1, CAMK2D, CCND2, CD8A, 
CDC42EP1, CDCA7L, CDH15, CDH4, CDS1, CERKL, CHID1, CHRND, CHSY1, CNNM1, 
COBLL1, COL5A1, CPLX2, CPOX, CRHR1, CTAGE1, CTBP2, CYP1B1, DACH1, DDIT4L, 
DFNB59, DHPS, DLGAP1-AS1, DLGAP2, DSE, DUSP4, EBF3, ECHDC2, EGR1, EGR4, ELFN1, 
EPHA4, EPHA8, FAHD1, FAM176C, FAM219A, FBXO27, FBXO44, FGFRL1, FLJ44511, 
FLJ45983, FLJ46257, FOS, FOXA1, FOXF2, FOXP1, FZD1, FZD10, GADD45B, GALNTL4, 
GBX2, GFPT2, GJB2, GLIS3, GPC1, GPC2, GPR160, GPSM1, GRIN3B, GULP1, H19, HBQ1, 
HDAC9, HLA-A, HLA-E, HMHA1, HRASLS, IAH1, IFT140, IGF2-AS, IQSEC2, IRX2, ITGB8, 
ITPKA, JDP2, JHDM1D, KBTBD11, KCNQ2, KCNQ4, KCNS2, KCTD15, KDELC1, KIAA0284, 
KIAA0513, KIF1A, KLF11, KLF15, KLF6, KLHDC7B, KREMEN2, LARGE, LCP1, LINC00461, 
LINC00473, LINC00628, LLGL2, LMF1, LOC100128946, LOC100131825, LOC100287042, 
LOC285577, LOC286083, LOC339807, LOC643923, LOC648987, LOC728613, LOC728716, 
LPAR3, LRRC32, LRRFIP1, LUZP2, LYNX1, MAFK, MAPRE2, MAST3, MBLAC1, MESDC1, 
MGMT, MIR3201, MIR3621, MIR3914-2, MIR4655, MIR4724, MIR581, MIR598, MKI67, 
MLPH, MMP17, MORN3, MST1P2, MYH11, MYO1B, NCR3LG1, NDST3, NFASC, NFIA, 
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NFIB, NGEF, NINL, NKX6-1, NOD2, NRIP3, NRL, NUDT16L1, OR1F1, OSMR, OVOL2, P4HA2, 
PALLD, PARD3B, PCDH9, PCGF5, PCOLCE-AS1, PDE4D, PDLIM1, PEX6, PGM2L1, PGPEP1L, 
PODXL2, POU3F1, PPM1E, PPM1H, PRAF2, PRELID1, PRR5L, PTGFRN, PTK6, PTMA, 
PTPN21, PWWP2B, RAB39B, RAD21L1, RASGEF1A, RASSF1, RASSF2, RBM33, RHBDD1, 
RHOB, RIMBP2, RNF130, ROR2, RPP40, RPS6KL1, RPUSD1, RRAGC, RSPO1, RUNDC3A, 
S1PR1, SALL1, SAMD13, SAMD4A, SARM1, SATB2-AS1, SCAMP1, SERTAD1, SFXN3, SFXN4, 
SLAIN1, SLC10A3, SLC16A14, SLC35G2, SLC3A2, SLC7A5P1, SLC7A5P2, SLCO5A1, 
SMARCA2, SNTG2, SOWAHC, ST6GAL1, STK17A, STK3, SUPT7L, SVIL, SYCE3, SYNPO, 
SYT17, TBR1, TFCP2L1, TGFA, TGFB1I1, TMEM171, TMEM179, TMEM181, TMEM200B, 
TMEM238, TNRC6C, TPBG, TPO, TRABD2A, TRABD2B, TSC22D3, TSC22D4, TUB, TUBA4A, 
UBB, USH1G, USP25, VDR, VEGFC, VGLL3, VLDLR, VPS37D, VWCE, WNT2B, WNT3, WNT6, 
ZDHHC2, ZNF160, ZNF20, ZNF396, ZNF423, ZNF442, ZNF470, ZNF512, ZNF528, ZNF611, 
ZNF669, ZNF717, ZNF789, ZNF808, ZNRF1  
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Appendix 6. List of 645 genes of which the methylations are decreased in G3KRev 
cells comparing with MiaPaca2 cells: 
AATK-AS1, ABCB6, ABHD8, ABLIM2, ACAP3, ACOT11, ACTB, ADAM19, ADAMTS3, 
ADAMTSL4, ADAP1, ADM, ADRB1, ADRB2, ADSSL1, AFF3, AGFG2, AKT3, ALG10, AMOTL1, 
AMOTL2, ANK1, ANKRD18DP, ANKRD29, APBB2, AQP7P1, ARAP3, ARC, ARHGAP23, 
ARHGAP29, ARHGAP5, ARHGEF6, ARNTL, ARTN, ARX, ASTE1, ATP8B2, ATRNL1, 
B4GALNT4, BAHCC1, BARX2, BATF3, BCL2L14, BCL7A, BCOR, BCR, BIK, BIN1, BLM, BMP6, 
BRSK2, BTNL9, C10orf10, C10orf129, C11orf70, C12orf57, C14orf132, C15orf59, 
C18orf25, C1orf115, C1orf170, C1orf204, C22orf34, C2CD4C, C3orf79, C6orf141, 
C9orf106, CABLES2, CACHD1, CACNA1D, CACNA1I, CACNG4, CACNG6, CAMK2B, 
CAMK2G, CAV2, CBFA2T3, CBLN2, CBR3-AS1, CBX4, CBX8, CCDC109B, CCDC149, 
CCDC174, CCDC71L, CCNO, CD34, CDC42EP1, CDH8, CDK6, CEBPA, CELSR1, CERS4, 
CHAC1, CHD7, CHRM4, CHST1, CIB2, CIDEA, CKAP4, CLDN4, CLK3, CMTM3, COL11A2, 
COL18A1, COL18A1-AS1, CPE, CPEB2, CPNE5, CPNE9, CRADD, CREG2, CRISPLD2, CSNK1E, 
CSTB, CT62, CTAG1A, CTAG1B, CTIF, CXCL1, CXXC5, CYB5R3, CYP1A1, CYP24A1, CYP2W1, 
DACT2, DBNDD1, DBP, DCAF5, DCTD, DDHD1, DEFA5, DGKZ, DHRS3, DIXDC1, DLK2, DLL1, 
DLX4, DNAJB1, DNAJB2, DNAJC6, DNMT3B, DOC2A, DOCK3, DPYSL2, DPYSL5, DSE, 
DUS3L, DUSP1, DUSP15, EBF3, ECE1, EDN2, EFNA5, EGLN3, EHBP1L1, EIF4E3, ELANE, 
ELFN1, ELOVL6, ENTHD2, EPHB3, EPS8L1, ERICH1, ESYT2, ETHE1, ETV2, EXD3, FAM105A, 
FAM184A, FAM196A, FAM198B, FAM20C, FAM211A, FAM213A, FAM27A, FAM65A, 
FAT4, FBXL16, FBXO6, FGF8, FGFRL1, FLJ42102, FMNL1, FMNL3, FOXF1, FOXQ1, FRG2, 
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FTMT, FUCA1, FUOM, GAB1, GAD1, GADD45B, GADD45G, GALNT11, GAS1, GBX1, GBX2, 
GFRA2, GGN, GINS2, GLCCI1, GLIS3, GMNC, GNG7, GORASP1, GPM6B, GPR132, 
GPR137B, GPR146, GPS1, GRIA2, GRM4, GSTO2, GUK1, H1F0, H3F3AP4, HDAC11, HDAC5, 
HERPUD2, HEY1, HHEX, HIPK3, HIVEP2, HLA-L, HLX, HNRNPD, HOXA3, HOXB1, HOXB2, 
HOXB9, HRC, HS3ST3B1, HSD11B2, HTR6, HUNK, IFITM3, IGF2BP2, IGSF3, IGSF8, IKBKE, 
IL15RA, IL17RA, IL20RB, IMPA2, INF2, INPP4B, INS, INSIG2, INTU, IRF2BPL, IRF5, IRS1, 
IRX3, ITGA9, JARID2, JMJD8, JUNB, KANK3, KCNC3, KCND3, KCNG3, KCNH3, KCNK18, 
KCNK9, KIAA0895L, KIAA1024, KIAA1324L, KIF1A, KIF6, KLC2, KLF13, KLF16, KLF4, KLF9, 
KLHL29, KLHL36, KLK6, KRT19P2, KSR2, L3MBTL2, LEF1-AS1, LGI3, LHB, LHX2, LHX4, LHX9, 
LIMCH1, LINC00112, LINC00290, LINC00461, LINC00518, LINC00523, LINC00667, 
LINC00674, LITAF, LMO1, LMO2, LMX1B, LOC100128511, LOC100271722, 
LOC100288974, LOC100506190, LOC255512, LOC283663, LOC283856, LOC283922, 
LOC284751, LOC339874, LOC400958, LOC643355, LOC645752, LOC648987, LPAL2, 
LPIN1, LPPR3, LRIG1, LRRC43, LRRCC1, LRRK1, LSP1P3, LTBP3, LYPD3, MAGED4, MAGIX, 
MAML3, MAMSTR, MAN1A1, MAN1C1, MAP1B, MAPK4, MARK1, MB21D1, MBOAT2, 
MCM5, MCOLN3, MDFIC, MECOM, MED12L, MEIS2, METTL10, MFI2, MFNG, MGAT4A, 
MGAT5B, MGC45800, MICALL1, MIDN, MIR101-1, MIR124-3, MIR130B, MIR153-1, 
MIR183, MIR3180-4, MIR339, MIR3615, MIR4456, MIR4634, MIR4664, MIR4686, 
MIR4787, MIR5189, MIR548I2, MIR573, MIR589, MLL3, MLLT6, MMEL1, MMP25, MN1, 
MNX1, MRPS10, MSI1, MUC17, MUC6, MYZAP, N4BP2L1, NAAA, NBL1, NCOA1, NCOR2, 
NDRG4, NDUFV2, NEDD4L, NEIL1, NFIA, NINJ2, NIPAL1, NIPAL4, NKX1-2, NOTUM, NPAS2, 
NPPC, NQO2, NR2F6, NR4A2, NRARP, NRN1, NSUN5, NTNG2, NTSR1, NUDT11, NUDT16, 
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NUP210, OAZ1, OR1F1, OSBPL7, OTOF, PABPC1L, PAOX, PAQR5, PAQR8, PARD6G, PARP9, 
PAX2, PCDHGC3, PDGFA, PDGFB, PDGFC, PDPR, PDZD2, PF4, PFKFB2, PHKA2-AS1, 
PIK3IP1, PIP5K1C, PITPNM2, PLEC, PLEKHA5, PLEKHG1, PLXNA2, PLXNA3, PMAIP1, 
PNMA2, PNPLA7, PPAPDC3, PPARG, PPCS, PPFIBP2, PPM1H, PPM1K, PPP1R14C, PPP4R4, 
PRDM1, PRDM16, PRDM6, PRKCQ, PRKCZ, PRR5, PRRX2, PRTG, PSD2, PSMD1, PTBP1, 
PTCH2, PTDSS2, PTGS1, PTPRK, PXDN, RAB26, RABAC1, RALGPS2, RANBP17, RAPGEF3, 
RAPGEF4, RASAL2-AS1, RASGEF1A, RASSF9, RBM20, RBMS1, RBPMS, RCAN2, RCCD1, 
RHPN1-AS1, RIMBP3B, RIPK4, RNF126, RNF152, RNF207, RNLS, RNPEPL1, RNU6ATAC, 
ROBO2, RSPH1, SAMD14, SBNO2, SCAND2, SCARNA3, SCD5, SCN8A, SCRN1, SDK1, SDK2, 
SEL1L3, SEMA4F, SEPHS2, SEPT11, SEPT5, SEPT8, SEPT9, SERPINE2, SFRP1, SH3BGRL2, 
SH3KBP1, SHOX2, SIM2, SKIDA1, SLC16A9, SLC22A20, SLC25A17, SLC25A27, SLC27A1, 
SLC29A4, SLC2A11, SLC37A2, SLC38A1, SLC44A3, SLC45A1, SLC4A8, SLC52A3, SLC6A8, 
SLC9A3R2, SMAD3, SMCR8, SMTNL2, SNCG, SNORA47, SNORD56B, SNORD82, SOCS3, 
SOX4, SOX6, SOX7, SOX8, SOX9, SPAG1, SPATA6, SPATA6L, SPC24, SPECC1, SPHK1, 
SQSTM1, SRCIN1, ST3GAL1, STK11, STOX2, STX17, SULF2, SUV420H1, SYNE4, SYNM, 
SYT12, SYT7, TACC1, TACC3, TALDO1, TAOK3, TBC1D14, TBC1D9, TBL1XR1, TBX2, TCF7, 
TDRD7, TEAD3, TENC1, TENM3, TFAP2A, THEMIS2, TIGD2, TJP3, TMC6, TMEM107, 
TMEM150C, TMEM179B, TMEM38A, TMEM56-RWDD3, TMTC2, TMX4, TNFSF9, TNNI3, 
TNRC18, TNS3, TP53TG1, TPBG, TPM1, TPM2, TPRN, TRIM62, TRPC3, TSKU, TSPAN14, 
TSPAN18, TSPAN5, TTC23L, TTC9, TTYH1, TXN2, TXNRD1, UBAC1, UBE2E2, UHRF1, ULK1, 
UNC5A, USP49, UST, VAMP3, VEGFC, VPS13D, VTI1B, VWA1, WDR81, WDR83, WIPF3, 
WNK2, WNT11, WNT2B, WNT4, WNT9A, WSCD2, WWC2-AS2, WWC3, ZBTB7A, 
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ZC3HAV1L, ZFAND2A, ZFAND4, ZFP36, ZNF136, ZNF14, ZNF223, ZNF304, ZNF362, 
ZNF385C, ZNF419, ZNF44, ZNF440, ZNF469, ZNF516, ZNF517, ZNF555, ZNF700, ZNF761, 
ZNF771, ZNF777, ZNF833P 
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